	chr	start	end	sym	trait
0	20	25294743.0	25390983.0	ABHD12	Liver enzyme levels (alkaline phosphatase)
1	20	25294743.0	25390983.0	ABHD12	Systemic lupus erythematosus
2	20	25006230.0	25058980.0	ACSS1	Cognitive performance
3	20	38748442.0	38772520.0	ACTR5	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease
4	20	50888919.0	50931240.0	ADNP	Prostate cancer
5	20	4220631.0	4249074.0	ADRA1D	Age-related nuclear cataracts
6	20	4220631.0	4249074.0	ADRA1D	Diisocyanate-induced asthma
7	20	4220631.0	4249074.0	ADRA1D	Facial morphology (factor 20)
8	20	4220631.0	4249074.0	ADRA1D	IgG glycosylation
9	20	4220631.0	4249074.0	ADRA1D	Microalbuminuria
10	20	4220631.0	4249074.0	ADRA1D	Mononucleosis
11	20	4220631.0	4249074.0	ADRA1D	Paneth cell defects in Crohn's disease
12	20	4220631.0	4249074.0	ADRA1D	Periodontitis (Mean PAL)
13	20	4220631.0	4249074.0	ADRA1D	Preeclampsia
14	20	34280268.0	34311802.0	AHCY	Liver fibrosis severity in HIV/hepatitis C co-infection
15	20	869899.0	916317.0	ANGPT4	3-hydroxy-1-methylpropylmercapturic acid levels in smokers
16	20	869899.0	916317.0	ANGPT4	3-hydroxypropylmercapturic acid levels in smokers
17	20	869899.0	916317.0	ANGPT4	Cognitive performance
18	20	869899.0	916317.0	ANGPT4	Daytime sleep phenotypes
19	20	869899.0	916317.0	ANGPT4	Estradiol plasma levels (breast cancer)
20	20	869899.0	916317.0	ANGPT4	Posterior cortical atrophy and Alzheimer's disease
21	20	869899.0	916317.0	ANGPT4	Social communication problems
22	20	58218495.0	58228653.0	ANKRD60	Height
23	20	3820524.0	3828837.0	AP5S1	Heart rate
24	20	3820524.0	3828837.0	AP5S1	Heart rate variability traits (RMSSD)
25	20	3820524.0	3828837.0	AP5S1	Heart rate variability traits (SDNN)
26	20	3820524.0	3828837.0	AP5S1	Hepcidin levels
27	20	3820524.0	3828837.0	AP5S1	Photic sneeze reflex
28	20	3820524.0	3828837.0	AP5S1	Resting heart rate
29	20	48921890.0	49036693.0	ARFGEF2	Anger
30	20	38601934.0	38651035.0	ARHGAP40	Schizophrenia
31	20	3471040.0	3651122.0	ATRN	Amyotrophic lateral sclerosis (sporadic)
32	20	3471040.0	3651122.0	ATRN	Anticoagulant levels
33	20	3471040.0	3651122.0	ATRN	Attention deficit hyperactivity disorder
34	20	3471040.0	3651122.0	ATRN	Blood protein levels
35	20	3471040.0	3651122.0	ATRN	Breast cancer
36	20	3471040.0	3651122.0	ATRN	Cholesterol, total
37	20	3471040.0	3651122.0	ATRN	Congenital left-sided heart lesions
38	20	3471040.0	3651122.0	ATRN	Coronary artery disease
39	20	3471040.0	3651122.0	ATRN	D-dimer levels
40	20	3471040.0	3651122.0	ATRN	Developmental dysplasia of the hip
41	20	3471040.0	3651122.0	ATRN	Diisocyanate-induced asthma
42	20	3471040.0	3651122.0	ATRN	Factor VII levels
43	20	3471040.0	3651122.0	ATRN	Freckling
44	20	3471040.0	3651122.0	ATRN	Height
45	20	3471040.0	3651122.0	ATRN	Hemostatic factors and hematological phenotypes
46	20	3471040.0	3651122.0	ATRN	High light scatter reticulocyte count
47	20	3471040.0	3651122.0	ATRN	Hip circumference
48	20	3471040.0	3651122.0	ATRN	Hip circumference adjusted for BMI
49	20	3471040.0	3651122.0	ATRN	Infant length
50	20	3471040.0	3651122.0	ATRN	Joint mobility (Beighton score)
51	20	3471040.0	3651122.0	ATRN	Lobe attachment (rater-scored or self-reported)
52	20	3471040.0	3651122.0	ATRN	Melanoma
53	20	3471040.0	3651122.0	ATRN	Migraine - clinic-based
54	20	3471040.0	3651122.0	ATRN	Neuroticism
55	20	3471040.0	3651122.0	ATRN	Obesity-related traits
56	20	3471040.0	3651122.0	ATRN	Protein C levels
57	20	3471040.0	3651122.0	ATRN	Prothrombin time
58	20	3471040.0	3651122.0	ATRN	QRS complex (Cornell)
59	20	3471040.0	3651122.0	ATRN	QRS interval (sulfonylurea treatment interaction)
60	20	3471040.0	3651122.0	ATRN	Response to paliperidone in schizophrenia (Multivariate)
61	20	3471040.0	3651122.0	ATRN	Response to paliperidone in schizophrenia (PANSS score)
62	20	3471040.0	3651122.0	ATRN	Reticulocyte count
63	20	3471040.0	3651122.0	ATRN	Reticulocyte fraction of red cells
64	20	3471040.0	3651122.0	ATRN	Spine bone size
65	20	3471040.0	3651122.0	ATRN	Thrombosis
66	20	3471040.0	3651122.0	ATRN	Total cholesterol levels
67	20	3471040.0	3651122.0	ATRN	Triglycerides
68	20	3471040.0	3651122.0	ATRN	Ulcerative colitis
69	20	3471040.0	3651122.0	ATRN	Venous thromboembolism
70	20	3471040.0	3651122.0	ATRN	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
71	20	3471040.0	3651122.0	ATRN	Waist-to-hip ratio adjusted for BMI in active individuals
72	20	3471040.0	3651122.0	ATRN	Waist-to-hip ratio adjusted for body mass index
73	20	49632945.0	49713878.0	B4GALT5	Urate levels in obese individuals
74	20	53936777.0	54070594.0	BCAS1	Bipolar disorder and schizophrenia
75	20	53936777.0	54070594.0	BCAS1	Breast cancer
76	20	53936777.0	54070594.0	BCAS1	Red cell distribution width
77	20	53936777.0	54070594.0	BCAS1	Resting heart rate
78	20	53936777.0	54070594.0	BCAS1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T
79	20	50794894.0	50882676.0	BCAS4	Breast cancer
80	20	31664452.0	31723989.0	BCL2L1	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder
81	20	31664452.0	31723989.0	BCL2L1	Platelet count
82	20	31664452.0	31723989.0	BCL2L1	Plateletcrit
83	20	31664452.0	31723989.0	BCL2L1	Putamen volume
84	20	31664452.0	31723989.0	BCL2L1	Subcortical brain region volumes
85	20	17493905.0	17569220.0	BFSP1	Obstructive sleep apnea trait (apnea hypopnea index)
86	20	6767664.0	6780280.0	BMP2	Obesity-related traits
87	20	57168748.0	57266629.0	BMP7	Facial morphology (factor 5, width of mouth relative to central midface)
88	20	57168748.0	57266629.0	BMP7	High light scatter reticulocyte count
89	20	57168748.0	57266629.0	BMP7	High light scatter reticulocyte percentage of red cells
90	20	57168748.0	57266629.0	BMP7	Monobrow
91	20	57168748.0	57266629.0	BMP7	Nose size
92	20	57168748.0	57266629.0	BMP7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder
93	20	57168748.0	57266629.0	BMP7	Reticulocyte count
94	20	57168748.0	57266629.0	BMP7	Reticulocyte fraction of red cells
95	20	38260149.0	38337505.0	BPI	Bipolar disorder and schizophrenia
96	20	38260149.0	38337505.0	BPI	Cerebrospinal fluid biomarker levels
97	20	38260149.0	38337505.0	BPI	Hepcidin levels
98	20	33161768.0	33181412.0	BPIFA2	Smooth-surface caries
99	20	3249305.0	3407625.0	C20orf194	Age at first birth
100	20	3249305.0	3407625.0	C20orf194	Asthma
101	20	3249305.0	3407625.0	C20orf194	Attention deficit hyperactivity disorder (combined symptoms)
102	20	3249305.0	3407625.0	C20orf194	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
103	20	3249305.0	3407625.0	C20orf194	Basophil percentage of granulocytes
104	20	3249305.0	3407625.0	C20orf194	Basophil percentage of white cells
105	20	3249305.0	3407625.0	C20orf194	Birth weight
106	20	3249305.0	3407625.0	C20orf194	Breast cancer
107	20	3249305.0	3407625.0	C20orf194	Cancer
108	20	3249305.0	3407625.0	C20orf194	Cancer (pleiotropy)
109	20	3249305.0	3407625.0	C20orf194	Dysphagia
110	20	3249305.0	3407625.0	C20orf194	Granulocyte percentage of myeloid white cells
111	20	3249305.0	3407625.0	C20orf194	Hair color
112	20	3249305.0	3407625.0	C20orf194	Height
113	20	3249305.0	3407625.0	C20orf194	High light scatter reticulocyte count
114	20	3249305.0	3407625.0	C20orf194	High light scatter reticulocyte percentage of red cells
115	20	3249305.0	3407625.0	C20orf194	Hip circumference adjusted for BMI
116	20	3249305.0	3407625.0	C20orf194	IFN-related cytopenia
117	20	3249305.0	3407625.0	C20orf194	IgG glycosylation
118	20	3249305.0	3407625.0	C20orf194	Immature fraction of reticulocytes
119	20	3249305.0	3407625.0	C20orf194	Inflammatory bowel disease
120	20	3249305.0	3407625.0	C20orf194	Iron status biomarkers (iron levels)
121	20	3249305.0	3407625.0	C20orf194	Iron status biomarkers (transferrin saturation)
122	20	3249305.0	3407625.0	C20orf194	Loneliness
123	20	3249305.0	3407625.0	C20orf194	Lymphocyte counts
124	20	3249305.0	3407625.0	C20orf194	Lymphocyte percentage of white cells
125	20	3249305.0	3407625.0	C20orf194	Mean corpuscular hemoglobin
126	20	3249305.0	3407625.0	C20orf194	Mean corpuscular volume
127	20	3249305.0	3407625.0	C20orf194	Monocyte count
128	20	3249305.0	3407625.0	C20orf194	Monocyte percentage of white cells
129	20	3249305.0	3407625.0	C20orf194	Post bronchodilator FEV1/FVC ratio
130	20	3249305.0	3407625.0	C20orf194	Red blood cell count
131	20	3249305.0	3407625.0	C20orf194	Red cell distribution width
132	20	3249305.0	3407625.0	C20orf194	Rubella
133	20	3249305.0	3407625.0	C20orf194	Smooth-surface caries
134	20	3249305.0	3407625.0	C20orf194	Stearic acid (18:0) levels
135	20	3249305.0	3407625.0	C20orf194	Subjective well-being
136	20	3249305.0	3407625.0	C20orf194	Type 1 diabetes nephropathy
137	20	3249305.0	3407625.0	C20orf194	Type 2 diabetes
138	20	3249305.0	3407625.0	C20orf194	Ulcerative colitis
139	20	3249305.0	3407625.0	C20orf194	White blood cell count (basophil)
140	20	5750393.0	5863912.0	C20orf196	Advanced age-related macular degeneration
141	20	5750393.0	5863912.0	C20orf196	Breast cancer
142	20	5750393.0	5863912.0	C20orf196	Cardiovascular risk factors (age interaction)
143	20	5750393.0	5863912.0	C20orf196	Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer
144	20	5750393.0	5863912.0	C20orf196	Emphysema imaging phenotypes
145	20	5750393.0	5863912.0	C20orf196	Facial morphology (factor 1, breadth of lateral portion of upper face)
146	20	5750393.0	5863912.0	C20orf196	Height
147	20	5750393.0	5863912.0	C20orf196	Hemoglobin concentration
148	20	5750393.0	5863912.0	C20orf196	Hippocampal atrophy
149	20	5750393.0	5863912.0	C20orf196	Information processing speed
150	20	5750393.0	5863912.0	C20orf196	Obesity-related traits
151	20	5750393.0	5863912.0	C20orf196	Positive affect
152	20	5750393.0	5863912.0	C20orf196	Prudent dietary pattern
153	20	5750393.0	5863912.0	C20orf196	Pulmonary function decline
154	20	5750393.0	5863912.0	C20orf196	Response to cytadine analogues (cytosine arabinoside)
155	20	5750393.0	5863912.0	C20orf196	Response to fenofibrate (adiponectin levels)
156	20	5750393.0	5863912.0	C20orf196	Systolic blood pressure
157	20	5750393.0	5863912.0	C20orf196	Verbal declarative memory
158	20	5750393.0	5863912.0	C20orf196	Warfarin maintenance dose
159	20	32631652.0	32673941.0	C20orf203	Basophil percentage of granulocytes
160	20	32631652.0	32673941.0	C20orf203	Basophil percentage of white cells
161	20	32631652.0	32673941.0	C20orf203	Subjective well-being
162	20	32631652.0	32673941.0	C20orf203	White blood cell count (basophil)
163	20	3753508.0	3768387.0	C20orf27	Mean corpuscular volume
164	20	3753508.0	3768387.0	C20orf27	Survival in colon cancer
165	20	270863.0	290778.0	C20orf96	Response to tocilizumab in rheumatoid arthritis
166	20	270863.0	290778.0	C20orf96	White matter integrity
167	20	62388632.0	62407285.0	CABLES2	Colorectal cancer
168	20	62388632.0	62407285.0	CABLES2	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes
169	20	56412112.0	56460387.0	CASS4	Alzheimer's disease (late onset)
170	20	56412112.0	56460387.0	CASS4	Interleukin-6 levels
171	20	56412112.0	56460387.0	CASS4	Platelet count
172	20	56412112.0	56460387.0	CASS4	Plateletcrit
173	20	32010450.0	32032180.0	CCM2L	Macrophage colony stimulating factor levels
174	20	46118272.0	46129863.0	CD40	Chronic hepatitis B infection
175	20	46118272.0	46129863.0	CD40	Rheumatoid arthritis
176	20	3786772.0	3806121.0	CDC25B	Bipolar disorder
177	20	3786772.0	3806121.0	CDC25B	Skin pigmentation
178	20	46173733.0	46308498.0	CDH22	IgG glycosylation
179	20	61252426.0	61940617.0	CDH4	&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels
180	20	61252426.0	61940617.0	CDH4	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
181	20	61252426.0	61940617.0	CDH4	Axial length
182	20	61252426.0	61940617.0	CDH4	Bipolar disorder (body mass index interaction)
183	20	61252426.0	61940617.0	CDH4	Cerebrospinal T-tau levels
184	20	61252426.0	61940617.0	CDH4	Cognitive decline rate in late mild cognitive impairment
185	20	61252426.0	61940617.0	CDH4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes
186	20	61252426.0	61940617.0	CDH4	Educational attainment (years of education)
187	20	61252426.0	61940617.0	CDH4	Longevity
188	20	61252426.0	61940617.0	CDH4	Migraine - clinic-based
189	20	61252426.0	61940617.0	CDH4	Multiple system atrophy
190	20	61252426.0	61940617.0	CDH4	Night sleep phenotypes
191	20	61252426.0	61940617.0	CDH4	Obesity-related traits
192	20	61252426.0	61940617.0	CDH4	Obstructive sleep apnea trait (average respiratory event duration)
193	20	61252426.0	61940617.0	CDH4	Sudden cardiac arrest
194	20	61252426.0	61940617.0	CDH4	Trans fatty acid levels
195	20	61252426.0	61940617.0	CDH4	Volumetric brain MRI
196	20	33358839.0	33401561.0	CDK5RAP1	Hair color
197	20	5126786.0	5197887.0	CDS2	Allergic disease (asthma, hay fever or eczema)
198	20	5126786.0	5197887.0	CDS2	Amyotrophic lateral sclerosis (sporadic)
199	20	5126786.0	5197887.0	CDS2	Asparaginase hypersensitivity in acute lymphoblastic leukemia
200	20	5126786.0	5197887.0	CDS2	Eosinophil percentage of white cells
201	20	5126786.0	5197887.0	CDS2	Interleukin-6 levels
202	20	5126786.0	5197887.0	CDS2	Lobe attachment (rater-scored or self-reported)
203	20	5126786.0	5197887.0	CDS2	Male infertility
204	20	5126786.0	5197887.0	CDS2	Nonsyndromic cleft lip with cleft palate
205	20	5126786.0	5197887.0	CDS2	Self-reported allergy
206	20	5126786.0	5197887.0	CDS2	Sitting height ratio
207	20	5126786.0	5197887.0	CDS2	Sum eosinophil basophil counts
208	20	5126786.0	5197887.0	CDS2	Tourette's syndrome or obsessive-compulsive disorder
209	20	5126786.0	5197887.0	CDS2	White matter microstructure in first episode schizophrenia (right anterior cingulate cortex)
210	20	3783851.0	3786690.0	CENPB	Bone mineral density
211	20	35455164.0	35519280.0	CEP250	Height
212	20	20052514.0	20360702.0	CFAP61	Exploratory eye movement dysfunction in schizophrenia (total eye scanning length)
213	20	20052514.0	20360702.0	CFAP61	Immune response to smallpox vaccine (IL-6)
214	20	20052514.0	20360702.0	CFAP61	Stem cell growth factor beta levels
215	20	20052514.0	20360702.0	CFAP61	White wine liking
216	20	41402101.0	41618494.0	CHD6	Gastric adenocarcinoma (histologically verified)
217	20	41402101.0	41618494.0	CHD6	High light scatter reticulocyte count
218	20	41402101.0	41618494.0	CHD6	High light scatter reticulocyte percentage of red cells
219	20	41402101.0	41618494.0	CHD6	Hippocampal atrophy
220	20	41402101.0	41618494.0	CHD6	Immature fraction of reticulocytes
221	20	41402101.0	41618494.0	CHD6	Reticulocyte count
222	20	41402101.0	41618494.0	CHD6	Reticulocyte fraction of red cells
223	20	41402101.0	41618494.0	CHD6	Verbal declarative memory
224	20	5911430.0	5925361.0	CHGB	Attention function in attention deficit hyperactive disorder
225	20	5911430.0	5925361.0	CHGB	Blood pressure
226	20	5911430.0	5925361.0	CHGB	Coronary artery disease
227	20	5911430.0	5925361.0	CHGB	Crohn's disease
228	20	5911430.0	5925361.0	CHGB	Diastolic blood pressure
229	20	5911430.0	5925361.0	CHGB	Hypertension
230	20	5911430.0	5925361.0	CHGB	Inflammatory bowel disease
231	20	5911430.0	5925361.0	CHGB	Lymphocyte counts
232	20	5911430.0	5925361.0	CHGB	Lymphocyte percentage of white cells
233	20	5911430.0	5925361.0	CHGB	Platelet distribution width
234	20	5911430.0	5925361.0	CHGB	Response to antipsychotic therapy (extrapyramidal side effects)
235	20	5911430.0	5925361.0	CHGB	Systolic blood pressure
236	20	5911430.0	5925361.0	CHGB	Ulcerative colitis
237	20	33811304.0	33854366.0	CHMP4B	Dysphagia
238	20	63343223.0	63378401.0	CHRNA4	Emphysema imaging phenotypes
239	20	63343223.0	63378401.0	CHRNA4	Facial morphology (factor 17, height of vermillion upper lip)
240	20	63343223.0	63378401.0	CHRNA4	Nicotine dependence
241	20	35954564.0	36030700.0	CNBD2	Hip circumference adjusted for BMI
242	20	32702691.0	32743997.0	COMMD7	Type 2 diabetes
243	20	6006090.0	6040053.0	CRLS1	Chronic kidney disease (severe chronic kidney disease vs normal kidney function) in type 1 diabetes
244	20	6006090.0	6040053.0	CRLS1	Glucose homeostasis traits
245	20	6006090.0	6040053.0	CRLS1	Lentiform nucleus volume
246	20	6006090.0	6040053.0	CRLS1	Metabolite levels (MHPG)
247	20	6006090.0	6040053.0	CRLS1	Type 1 diabetes nephropathy
248	20	49046246.0	49096960.0	CSE1L	Intelligence
249	20	49046246.0	49096960.0	CSE1L	Intelligence (multi-trait analysis)
250	20	49046246.0	49096960.0	CSE1L	Non-response to citalopram or escitalopram and depression
251	20	49046246.0	49096960.0	CSE1L	Positive affect
252	20	49046246.0	49096960.0	CSE1L	Subjective well-being
253	20	473591.0	543821.0	CSNK2A1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
254	20	473591.0	543821.0	CSNK2A1	Alcohol consumption
255	20	473591.0	543821.0	CSNK2A1	Allergic disease (asthma, hay fever or eczema)
256	20	473591.0	543821.0	CSNK2A1	Alzheimer disease and age of onset
257	20	473591.0	543821.0	CSNK2A1	Amyotrophic lateral sclerosis
258	20	473591.0	543821.0	CSNK2A1	Amyotrophic lateral sclerosis (sporadic)
259	20	473591.0	543821.0	CSNK2A1	Anger
260	20	473591.0	543821.0	CSNK2A1	Anti-saccade response
261	20	473591.0	543821.0	CSNK2A1	Asparaginase hypersensitivity in acute lymphoblastic leukemia
262	20	473591.0	543821.0	CSNK2A1	Atopic dermatitis
263	20	473591.0	543821.0	CSNK2A1	Atrial fibrillation
264	20	473591.0	543821.0	CSNK2A1	Attention deficit hyperactivity disorder
265	20	473591.0	543821.0	CSNK2A1	Attention deficit hyperactivity disorder (combined symptoms)
266	20	473591.0	543821.0	CSNK2A1	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
267	20	473591.0	543821.0	CSNK2A1	Attention deficit hyperactivity disorder (time to onset)
268	20	473591.0	543821.0	CSNK2A1	BMI (adjusted for smoking behaviour)
269	20	473591.0	543821.0	CSNK2A1	BMI in non-smokers
270	20	473591.0	543821.0	CSNK2A1	Bipolar disorder
271	20	473591.0	543821.0	CSNK2A1	Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder
272	20	473591.0	543821.0	CSNK2A1	Bipolar disorder (body mass index interaction)
273	20	473591.0	543821.0	CSNK2A1	Bipolar disorder and schizophrenia
274	20	473591.0	543821.0	CSNK2A1	Bipolar disorder or attention deficit hyperactivity disorder
275	20	473591.0	543821.0	CSNK2A1	Body mass index
276	20	473591.0	543821.0	CSNK2A1	Body mass index (joint analysis main effects and smoking interaction)
277	20	473591.0	543821.0	CSNK2A1	Body mass index in non-asthmatics
278	20	473591.0	543821.0	CSNK2A1	Breast cancer
279	20	473591.0	543821.0	CSNK2A1	Calcium levels
280	20	473591.0	543821.0	CSNK2A1	Cerebrospinal fluid AB1-42 levels
281	20	473591.0	543821.0	CSNK2A1	Cognitive ability
282	20	473591.0	543821.0	CSNK2A1	Cognitive ability (multi-trait analysis)
283	20	473591.0	543821.0	CSNK2A1	Colonoscopy-negative controls vs population controls
284	20	473591.0	543821.0	CSNK2A1	Colorectal adenoma (advanced)
285	20	473591.0	543821.0	CSNK2A1	Colorectal cancer
286	20	473591.0	543821.0	CSNK2A1	Colorectal cancer (oestrogen-progestogen hormone therapy interaction)
287	20	473591.0	543821.0	CSNK2A1	Coronary artery aneurysm in Kawasaki disease
288	20	473591.0	543821.0	CSNK2A1	Coronary artery disease
289	20	473591.0	543821.0	CSNK2A1	Depression
290	20	473591.0	543821.0	CSNK2A1	Diastolic blood pressure
291	20	473591.0	543821.0	CSNK2A1	Educational attainment (years of education)
292	20	473591.0	543821.0	CSNK2A1	Eosinophil percentage of white cells
293	20	473591.0	543821.0	CSNK2A1	Facial morphology (factor 23)
294	20	473591.0	543821.0	CSNK2A1	Glomerular filtration rate
295	20	473591.0	543821.0	CSNK2A1	Glomerular filtration rate (creatinine)
296	20	473591.0	543821.0	CSNK2A1	Granulocyte percentage of myeloid white cells
297	20	473591.0	543821.0	CSNK2A1	Gut microbiota (beta diversity)
298	20	473591.0	543821.0	CSNK2A1	Gut microbiota (functional units)
299	20	473591.0	543821.0	CSNK2A1	Hair morphology
300	20	473591.0	543821.0	CSNK2A1	Height
301	20	473591.0	543821.0	CSNK2A1	Hematocrit
302	20	473591.0	543821.0	CSNK2A1	Hemoglobin
303	20	473591.0	543821.0	CSNK2A1	Hepatitis B
304	20	473591.0	543821.0	CSNK2A1	High light scatter reticulocyte count
305	20	473591.0	543821.0	CSNK2A1	High light scatter reticulocyte percentage of red cells
306	20	473591.0	543821.0	CSNK2A1	IgG glycosylation
307	20	473591.0	543821.0	CSNK2A1	Immature fraction of reticulocytes
308	20	473591.0	543821.0	CSNK2A1	Infant length
309	20	473591.0	543821.0	CSNK2A1	Inflammatory bowel disease
310	20	473591.0	543821.0	CSNK2A1	Inflammatory skin disease
311	20	473591.0	543821.0	CSNK2A1	Intelligence
312	20	473591.0	543821.0	CSNK2A1	Intelligence (multi-trait analysis)
313	20	473591.0	543821.0	CSNK2A1	Interleukin-6 levels
314	20	473591.0	543821.0	CSNK2A1	Life satisfaction
315	20	473591.0	543821.0	CSNK2A1	Lobe attachment (rater-scored or self-reported)
316	20	473591.0	543821.0	CSNK2A1	Longitudinal change in brain amyloid plaque burden
317	20	473591.0	543821.0	CSNK2A1	Lymphocyte counts
318	20	473591.0	543821.0	CSNK2A1	Male infertility
319	20	473591.0	543821.0	CSNK2A1	Mean corpuscular hemoglobin
320	20	473591.0	543821.0	CSNK2A1	Mean corpuscular volume
321	20	473591.0	543821.0	CSNK2A1	Modified Stumvoll Insulin Sensitivity Index (BMI interaction)
322	20	473591.0	543821.0	CSNK2A1	Molar-incisor hypomineralization
323	20	473591.0	543821.0	CSNK2A1	Monocyte count
324	20	473591.0	543821.0	CSNK2A1	Monocyte percentage of white cells
325	20	473591.0	543821.0	CSNK2A1	Multiple myeloma
326	20	473591.0	543821.0	CSNK2A1	Multiple sclerosis
327	20	473591.0	543821.0	CSNK2A1	Narcolepsy with cataplexy
328	20	473591.0	543821.0	CSNK2A1	Nephrotic syndrome (acquired)
329	20	473591.0	543821.0	CSNK2A1	Night sleep phenotypes
330	20	473591.0	543821.0	CSNK2A1	Non-response to citalopram or escitalopram and depression
331	20	473591.0	543821.0	CSNK2A1	Nonsyndromic cleft lip with cleft palate
332	20	473591.0	543821.0	CSNK2A1	Nucleus accumbens volume in trauma-exposed individuals
333	20	473591.0	543821.0	CSNK2A1	Obesity
334	20	473591.0	543821.0	CSNK2A1	Obesity-related traits
335	20	473591.0	543821.0	CSNK2A1	Osteoarthritis (hip)
336	20	473591.0	543821.0	CSNK2A1	Palmitic acid (16:0) levels
337	20	473591.0	543821.0	CSNK2A1	Polycystic ovary syndrome
338	20	473591.0	543821.0	CSNK2A1	Positive affect
339	20	473591.0	543821.0	CSNK2A1	Post bronchodilator FEV1
340	20	473591.0	543821.0	CSNK2A1	Post bronchodilator FEV1/FVC ratio in COPD
341	20	473591.0	543821.0	CSNK2A1	Prostate cancer
342	20	473591.0	543821.0	CSNK2A1	Psoriasis
343	20	473591.0	543821.0	CSNK2A1	Psoriasis vulgaris
344	20	473591.0	543821.0	CSNK2A1	QT interval
345	20	473591.0	543821.0	CSNK2A1	QT interval (drug interaction)
346	20	473591.0	543821.0	CSNK2A1	Reading disability or specific language impairment (pleiotropy)
347	20	473591.0	543821.0	CSNK2A1	Red blood cell count
348	20	473591.0	543821.0	CSNK2A1	Red cell distribution width
349	20	473591.0	543821.0	CSNK2A1	Response to treatment for acute lymphoblastic leukemia
350	20	473591.0	543821.0	CSNK2A1	Resting heart rate
351	20	473591.0	543821.0	CSNK2A1	Reticulocyte count
352	20	473591.0	543821.0	CSNK2A1	Reticulocyte fraction of red cells
353	20	473591.0	543821.0	CSNK2A1	Rheumatic fever
354	20	473591.0	543821.0	CSNK2A1	Schizophrenia
355	20	473591.0	543821.0	CSNK2A1	Seasonality
356	20	473591.0	543821.0	CSNK2A1	Self-reported allergy
357	20	473591.0	543821.0	CSNK2A1	Serum parathyroid hormone levels
358	20	473591.0	543821.0	CSNK2A1	Sitting height ratio
359	20	473591.0	543821.0	CSNK2A1	Stem cell growth factor beta levels
360	20	473591.0	543821.0	CSNK2A1	Subcutaneous adipose tissue
361	20	473591.0	543821.0	CSNK2A1	Subjective well-being
362	20	473591.0	543821.0	CSNK2A1	Sum eosinophil basophil counts
363	20	473591.0	543821.0	CSNK2A1	Systemic lupus erythematosus
364	20	473591.0	543821.0	CSNK2A1	Testicular germ cell tumor
365	20	473591.0	543821.0	CSNK2A1	Thyroid peroxidase antibody positivity
366	20	473591.0	543821.0	CSNK2A1	Tonometry
367	20	473591.0	543821.0	CSNK2A1	Tourette's syndrome or obsessive-compulsive disorder
368	20	473591.0	543821.0	CSNK2A1	Tuberculosis
369	20	473591.0	543821.0	CSNK2A1	Type 2 diabetes (age of onset)
370	20	473591.0	543821.0	CSNK2A1	Ulcerative colitis
371	20	473591.0	543821.0	CSNK2A1	Urate levels in obese individuals
372	20	473591.0	543821.0	CSNK2A1	Urinary tract infection frequency
373	20	473591.0	543821.0	CSNK2A1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T
374	20	473591.0	543821.0	CSNK2A1	Vitamin D levels
375	20	473591.0	543821.0	CSNK2A1	Vitiligo
376	20	473591.0	543821.0	CSNK2A1	Waist circumference
377	20	473591.0	543821.0	CSNK2A1	Waist circumference adjusted for BMI (adjusted for smoking behaviour)
378	20	473591.0	543821.0	CSNK2A1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
379	20	473591.0	543821.0	CSNK2A1	Waist circumference adjusted for BMI in non-smokers
380	20	473591.0	543821.0	CSNK2A1	Waist-hip ratio
381	20	473591.0	543821.0	CSNK2A1	Warfarin maintenance dose
382	20	473591.0	543821.0	CSNK2A1	White matter hyperintensity burden
383	20	473591.0	543821.0	CSNK2A1	White matter microstructure in first episode schizophrenia (right anterior cingulate cortex)
384	20	23747553.0	23751268.0	CST1	Blood protein levels
385	20	23626706.0	23638473.0	CST3	Blood protein levels
386	20	23626706.0	23638473.0	CST3	Chronic kidney disease
387	20	23626706.0	23638473.0	CST3	Plasma cystastin c levels in acute coronary syndrome
388	20	57495966.0	57525652.0	CTCFL	Response to cytadine analogues (cytosine arabinoside)
389	20	37693955.0	37872129.0	CTNNBL1	Bone mineral density
390	20	37693955.0	37872129.0	CTNNBL1	Cognitive decline rate in late mild cognitive impairment
391	20	37693955.0	37872129.0	CTNNBL1	Visceral adipose tissue adjusted for BMI
392	20	58995185.0	59007247.0	CTSZ	Platelet distribution width
393	20	54153449.0	54173973.0	CYP24A1	Anti-saccade response
394	20	54153449.0	54173973.0	CYP24A1	Calcium levels
395	20	54153449.0	54173973.0	CYP24A1	Post bronchodilator FEV1
396	20	3190350.0	3204685.0	DDRGK1	Macrophage colony stimulating factor levels
397	20	3190350.0	3204685.0	DDRGK1	Migraine
398	20	3190350.0	3204685.0	DDRGK1	Night sleep phenotypes
399	20	3190350.0	3204685.0	DDRGK1	Response to hepatitis C treatment
400	20	49219295.0	49244077.0	DDX27	Intelligence (multi-trait analysis)
401	20	31368618.0	31373923.0	DEFB118	Prudent dietary pattern
402	20	87250.0	97094.0	DEFB125	3-hydroxy-1-methylpropylmercapturic acid levels in smokers
403	20	87250.0	97094.0	DEFB125	3-hydroxypropylmercapturic acid levels in smokers
404	20	87250.0	97094.0	DEFB125	Cognitive performance
405	20	87250.0	97094.0	DEFB125	Daytime sleep phenotypes
406	20	87250.0	97094.0	DEFB125	Initial pursuit acceleration
407	20	87250.0	97094.0	DEFB125	Initial pursuit acceleration in psychotic disorders
408	20	87250.0	97094.0	DEFB125	Neutrophil count
409	20	87250.0	97094.0	DEFB125	Posterior cortical atrophy and Alzheimer's disease
410	20	87250.0	97094.0	DEFB125	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)
411	20	87250.0	97094.0	DEFB125	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)
412	20	87250.0	97094.0	DEFB125	Social communication problems
413	20	142369.0	145751.0	DEFB126	Mean platelet volume
414	20	142369.0	145751.0	DEFB126	Mood disorder in prion disease
415	20	142369.0	145751.0	DEFB126	Non-alcoholic fatty liver disease histology (other)
416	20	157470.0	159163.0	DEFB127	Body mass index
417	20	157470.0	159163.0	DEFB127	TRAIL levels
418	20	157470.0	159163.0	DEFB127	Thyroid-associated orbitopathy in graves' disease
419	20	187853.0	189681.0	DEFB128	Alcoholic chronic pancreatitis
420	20	187853.0	189681.0	DEFB128	C-reactive protein (red blood cell fatty acid level interaction)
421	20	187853.0	189681.0	DEFB128	Fasting insulin (dietary factor interaction)
422	20	187853.0	189681.0	DEFB128	Homeostasis model assessment of insulin resistance (dietary factor interaction)
423	20	227258.0	229886.0	DEFB129	Age of smoking initiation
424	20	227258.0	229886.0	DEFB129	Gout
425	20	227258.0	229886.0	DEFB129	Obesity-related traits
426	20	227258.0	229886.0	DEFB129	Vitamin D levels
427	20	257736.0	261096.0	DEFB132	3-hydroxy-1-methylpropylmercapturic acid levels in smokers
428	20	257736.0	261096.0	DEFB132	Colorectal or endometrial cancer
429	20	257736.0	261096.0	DEFB132	Obesity-related traits
430	20	257736.0	261096.0	DEFB132	Red blood cell count
431	20	38962299.0	39039723.0	DHX35	Itch intensity from mosquito bite adjusted by bite size
432	20	62877738.0	62937952.0	DIDO1	Menopause (age at onset)
433	20	36306336.0	36528637.0	DLGAP4	High light scatter reticulocyte count
434	20	36306336.0	36528637.0	DLGAP4	Reticulocyte count
435	20	36306336.0	36528637.0	DLGAP4	Reticulocyte fraction of red cells
436	20	32762385.0	32809356.0	DNMT3B	Attention deficit hyperactivity disorder (combined symptoms)
437	20	32762385.0	32809356.0	DNMT3B	Inflammatory bowel disease
438	20	32762385.0	32809356.0	DNMT3B	Lymphocyte counts
439	20	32762385.0	32809356.0	DNMT3B	Lymphocyte percentage of white cells
440	20	45791937.0	45811427.0	DNTTIP1	Mean platelet volume
441	20	54475597.0	54651171.0	DOK5	Functional MRI
442	20	17569863.0	17609919.0	DSTN	Presence of antiphospholipid antibodies
443	20	18567453.0	18763917.0	DTD1	Night sleep phenotypes
444	20	18567453.0	18763917.0	DTD1	Obesity-related traits
445	20	18383367.0	18467281.0	DZANK1	Mean platelet volume
446	20	18383367.0	18467281.0	DZANK1	Platelet distribution width
447	20	33675683.0	33686404.0	E2F1	Asthma
448	20	35115357.0	35147364.0	EDEM2	Protein C levels
449	20	35115357.0	35147364.0	EDEM2	Prothrombin time
450	20	32858923.0	32961609.0	EFCAB8	Attention deficit hyperactivity disorder (combined symptoms)
451	20	32858923.0	32961609.0	EFCAB8	Type 1 diabetes nephropathy
452	20	35278907.0	35284985.0	EIF6	Freckling
453	20	25195693.0	25226729.0	ENTPD6	Allergic rhinitis
454	20	36091504.0	36232799.0	EPB41L1	Height
455	20	36091504.0	36232799.0	EPB41L1	Hip circumference
456	20	13714322.0	13784886.0	ESF1	Intelligence (childhood)
457	20	46894624.0	47188844.0	EYA2	Brain volume in infants (intracranial brain volume)
458	20	46894624.0	47188844.0	EYA2	Creutzfeldt-Jakob disease
459	20	46894624.0	47188844.0	EYA2	Creutzfeldt-Jakob disease (sporadic)
460	20	46894624.0	47188844.0	EYA2	Creutzfeldt-Jakob disease (variant)
461	20	46894624.0	47188844.0	EYA2	Facial morphology (factor 19)
462	20	46894624.0	47188844.0	EYA2	Prion diseases
463	20	46894624.0	47188844.0	EYA2	Thiazide-induced adverse metabolic effects in hypertensive patients
464	20	46894624.0	47188844.0	EYA2	Type 2 diabetes
465	20	46894624.0	47188844.0	EYA2	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
466	20	46894624.0	47188844.0	EYA2	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
467	20	46894624.0	47188844.0	EYA2	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
468	20	46894624.0	47188844.0	EYA2	Waist-to-hip ratio adjusted for BMI in active individuals
469	20	46894624.0	47188844.0	EYA2	Waist-to-hip ratio adjusted for body mass index
470	20	833715.0	857463.0	FAM110A	Obesity-related traits
471	20	833715.0	857463.0	FAM110A	Response to paliperidone in schizophrenia (Multivariate)
472	20	56533246.0	56536520.0	FAM209B	Obesity-related traits
473	20	38926312.0	38953106.0	FAM83D	Measles
474	20	3146519.0	3159897.0	FASTKD5	Eosinophil counts
475	20	6074845.0	6123544.0	FERMT1	Crohn's disease
476	20	6074845.0	6123544.0	FERMT1	Inflammatory bowel disease
477	20	6074845.0	6123544.0	FERMT1	Metabolite levels  (X-11787)
478	20	6074845.0	6123544.0	FERMT1	Monocyte chemoattractant protein-3 levels
479	20	6074845.0	6123544.0	FERMT1	Survival in colon cancer
480	20	1368978.0	1393172.0	FKBP1A	Intelligence (childhood)
481	20	14322988.0	14337616.0	FLRT3	Mood disorder in prion disease
482	20	31844301.0	31845619.0	FOXS1	Mean corpuscular hemoglobin
483	20	35433347.0	35454746.0	GDF5	Height
484	20	35433347.0	35454746.0	GDF5	Hip circumference
485	20	35433347.0	35454746.0	GDF5	Hip circumference adjusted for BMI
486	20	35433347.0	35454746.0	GDF5	Infant length
487	20	35433347.0	35454746.0	GDF5	Joint mobility (Beighton score)
488	20	35433347.0	35454746.0	GDF5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
489	20	35433347.0	35454746.0	GDF5	Waist-to-hip ratio adjusted for BMI in active individuals
490	20	35433347.0	35454746.0	GDF5	Waist-to-hip ratio adjusted for body mass index
491	20	34844720.0	34872860.0	GGT7	Coronary artery disease
492	20	34844720.0	34872860.0	GGT7	Neuroticism
493	20	58839718.0	58911192.0	GNAS	Event-related brain oscillations
494	20	58839718.0	58911192.0	GNAS	Platelet distribution width
495	20	58839718.0	58911192.0	GNAS	Post bronchodilator FEV1/FVC ratio
496	20	58839718.0	58911192.0	GNAS	Renal function-related traits (BUN)
497	20	58839718.0	58911192.0	GNAS	Sulfasalazine-induced agranulocytosis
498	20	58839718.0	58911192.0	GNAS	Waist circumference adjusted for body mass index
499	20	5544404.0	5611026.0	GPCPD1	3-hydroxypropylmercapturic acid levels in smokers
500	20	5544404.0	5611026.0	GPCPD1	Body mass index
501	20	5544404.0	5611026.0	GPCPD1	Initial pursuit acceleration
502	20	5544404.0	5611026.0	GPCPD1	Migraine without aura
503	20	5544404.0	5611026.0	GPCPD1	Motion sickness
504	20	5544404.0	5611026.0	GPCPD1	Occipital cortical area (total cortical area interaction)
505	20	34928430.0	34955817.0	GSS	QRS complex (Cornell)
506	20	7882981.0	7940474.0	HAO1	Hepatocyte growth factor levels
507	20	7882981.0	7940474.0	HAO1	QT interval
508	20	32052188.0	32101856.0	HCK	Fear of minor pain
509	20	32052188.0	32101856.0	HCK	Response to hepatitis C treatment
510	20	31514428.0	31577923.0	HM13	Eosinophil counts
511	20	44355700.0	44434596.0	HNF4A	C-reactive protein
512	20	44355700.0	44434596.0	HNF4A	C-reactive protein levels
513	20	44355700.0	44434596.0	HNF4A	C-reactive protein levels or HDL-cholesterol levels (pleiotropy)
514	20	44355700.0	44434596.0	HNF4A	C-reactive protein levels or LDL-cholesterol levels (pleiotropy)
515	20	44355700.0	44434596.0	HNF4A	C-reactive protein levels or total cholesterol levels (pleiotropy)
516	20	44355700.0	44434596.0	HNF4A	Cholesterol, total
517	20	44355700.0	44434596.0	HNF4A	Fibrinogen levels
518	20	44355700.0	44434596.0	HNF4A	Granulocyte count
519	20	44355700.0	44434596.0	HNF4A	Gut microbiota (bacterial taxa)
520	20	44355700.0	44434596.0	HNF4A	HDL cholesterol
521	20	44355700.0	44434596.0	HNF4A	Hematocrit
522	20	44355700.0	44434596.0	HNF4A	Myeloid white cell count
523	20	44355700.0	44434596.0	HNF4A	Neutrophil count
524	20	44355700.0	44434596.0	HNF4A	Neutrophil percentage of white cells
525	20	44355700.0	44434596.0	HNF4A	Sum basophil neutrophil counts
526	20	44355700.0	44434596.0	HNF4A	Sum neutrophil eosinophil counts
527	20	44355700.0	44434596.0	HNF4A	Type 2 diabetes
528	20	3732667.0	3753111.0	HSPA12B	Retinopathy in non-diabetics
529	20	3732667.0	3753111.0	HSPA12B	Squamous cell carcinoma
530	20	13221771.0	13300651.0	ISM1	Metabolite levels  (X-11787)
531	20	13221771.0	13300651.0	ISM1	Night sleep phenotypes
532	20	13221771.0	13300651.0	ISM1	Survival in colon cancer
533	20	3208868.0	3223870.0	ITPA	Chronic hepatitis C infection
534	20	3208868.0	3223870.0	ITPA	Chronic obstructive pulmonary disease
535	20	3208868.0	3223870.0	ITPA	Inflammatory bowel disease
536	20	3208868.0	3223870.0	ITPA	Ribavirin-induced anemia
537	20	10637684.0	10674107.0	JAG1	Bone mineral density
538	20	44111695.0	44187578.0	JPH2	Clozapine-induced agranulocytosis
539	20	44111695.0	44187578.0	JPH2	Glomerular filtration rate (creatinine)
540	20	49293394.0	49484297.0	KCNB1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
541	20	49293394.0	49484297.0	KCNB1	Colonoscopy-negative controls vs population controls
542	20	49293394.0	49484297.0	KCNB1	Intelligence (multi-trait analysis)
543	20	49293394.0	49484297.0	KCNB1	Obesity-related traits
544	20	49293394.0	49484297.0	KCNB1	QT interval
545	20	49293394.0	49484297.0	KCNB1	Schizophrenia
546	20	49293394.0	49484297.0	KCNB1	White matter hyperintensity burden
547	20	63400210.0	63472677.0	KCNQ2	Tuberculosis
548	20	45092310.0	45101112.0	KCNS1	Bipolar disorder
549	20	45092310.0	45101112.0	KCNS1	Mean platelet volume
550	20	38210488.0	38260772.0	KIAA1755	Heart rate
551	20	38210488.0	38260772.0	KIAA1755	Heart rate variability traits (RMSSD)
552	20	38210488.0	38260772.0	KIAA1755	Heart rate variability traits (SDNN)
553	20	38210488.0	38260772.0	KIAA1755	Photic sneeze reflex
554	20	38210488.0	38260772.0	KIAA1755	Resting heart rate
555	20	16272104.0	16573434.0	KIF16B	Asthma
556	20	16272104.0	16573434.0	KIF16B	Emphysema imaging phenotypes
557	20	16272104.0	16573434.0	KIF16B	Ileal carcinoids
558	20	16272104.0	16573434.0	KIF16B	Post bronchodilator FEV1/FVC ratio
559	20	16272104.0	16573434.0	KIF16B	Response to taxane treatment (docetaxel)
560	20	16272104.0	16573434.0	KIF16B	Type 1 diabetes
561	20	32277664.0	32335011.0	KIF3B	Granulocyte percentage of myeloid white cells
562	20	32277664.0	32335011.0	KIF3B	Monocyte percentage of white cells
563	20	21125983.0	21246622.0	KIZ	Height
564	20	21125983.0	21246622.0	KIZ	Lupus nephritis in systemic lupus erythematosus
565	20	21125983.0	21246622.0	KIZ	Peanut allergy
566	20	62307955.0	62367312.0	LAMA5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers
567	20	62307955.0	62367312.0	LAMA5	Colorectal cancer
568	20	62307955.0	62367312.0	LAMA5	Pelvic organ prolapse
569	20	38346356.0	38377023.0	LBP	IgG glycosylation
570	20	38346356.0	38377023.0	LBP	Periodontitis (DPAL)
571	20	6040778.0	6054049.0	LRRN4	Cough in response to angiotensin-converting enzyme inhibitor drugs
572	20	3162617.0	3173592.0	LZTS3	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder
573	20	3162617.0	3173592.0	LZTS3	Platelet count
574	20	3162617.0	3173592.0	LZTS3	Plateletcrit
575	20	3162617.0	3173592.0	LZTS3	Putamen volume
576	20	3162617.0	3173592.0	LZTS3	Subcortical brain region volumes
577	20	13995369.0	16053197.0	MACROD2	3-hydroxy-1-methylpropylmercapturic acid levels in smokers
578	20	13995369.0	16053197.0	MACROD2	Advanced glycation end-product levels
579	20	13995369.0	16053197.0	MACROD2	Amyotrophic lateral sclerosis (sporadic)
580	20	13995369.0	16053197.0	MACROD2	Autism
581	20	13995369.0	16053197.0	MACROD2	Body mass index
582	20	13995369.0	16053197.0	MACROD2	Circulating myeloperoxidase levels (serum)
583	20	13995369.0	16053197.0	MACROD2	Common carotid intima-media thickness in HIV infection
584	20	13995369.0	16053197.0	MACROD2	Coronary artery aneurysm in Kawasaki disease
585	20	13995369.0	16053197.0	MACROD2	Eating disorders
586	20	13995369.0	16053197.0	MACROD2	Epstein-Barr virus copy number in lymphoblastoid cell lines
587	20	13995369.0	16053197.0	MACROD2	Facial morphology (factor 10, width of nasal floor)
588	20	13995369.0	16053197.0	MACROD2	Intelligence (multi-trait analysis)
589	20	13995369.0	16053197.0	MACROD2	Interleukin-10 levels
590	20	13995369.0	16053197.0	MACROD2	Interleukin-12p70 levels
591	20	13995369.0	16053197.0	MACROD2	Male fertility
592	20	13995369.0	16053197.0	MACROD2	Mean platelet volume
593	20	13995369.0	16053197.0	MACROD2	Mood disorder in prion disease
594	20	13995369.0	16053197.0	MACROD2	Non-alcoholic fatty liver disease histology (other)
595	20	13995369.0	16053197.0	MACROD2	Obesity (extreme)
596	20	13995369.0	16053197.0	MACROD2	Obesity-related traits
597	20	13995369.0	16053197.0	MACROD2	Pediatric bone mineral content (hip)
598	20	13995369.0	16053197.0	MACROD2	Pediatric bone mineral density (femoral neck)
599	20	13995369.0	16053197.0	MACROD2	Pediatric bone mineral density (hip)
600	20	13995369.0	16053197.0	MACROD2	Percentage gas trapping
601	20	13995369.0	16053197.0	MACROD2	Peripheral arterial disease (traffic-related air pollution interaction)
602	20	13995369.0	16053197.0	MACROD2	Platelet distribution width
603	20	13995369.0	16053197.0	MACROD2	Plateletcrit
604	20	13995369.0	16053197.0	MACROD2	Presence of antiphospholipid antibodies
605	20	13995369.0	16053197.0	MACROD2	TRAIL levels
606	20	13995369.0	16053197.0	MACROD2	Thyroid-associated orbitopathy in graves' disease
607	20	13995369.0	16053197.0	MACROD2	White matter lesion progression
608	20	32819893.0	32850405.0	MAPRE1	Attention deficit hyperactivity disorder (combined symptoms)
609	20	32819893.0	32850405.0	MAPRE1	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
610	20	32819893.0	32850405.0	MAPRE1	Iron status biomarkers (transferrin saturation)
611	20	45293445.0	45308529.0	MATN4	Parental longevity (mother's age at death)
612	20	3846799.0	3876123.0	MAVS	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease
613	20	3846799.0	3876123.0	MAVS	Modified Stumvoll Insulin Sensitivity Index (BMI interaction)
614	20	3846799.0	3876123.0	MAVS	Schizophrenia
615	20	3846799.0	3876123.0	MAVS	circulating leptin levels
616	20	3846799.0	3876123.0	MAVS	circulating leptin levels adjusted for BMI
617	20	5950652.0	5998977.0	MCM8	Breast cancer
618	20	5950652.0	5998977.0	MCM8	HIV-1 viral setpoint
619	20	5950652.0	5998977.0	MCM8	Intelligence (multi-trait analysis)
620	20	5950652.0	5998977.0	MCM8	Menarche and menopause (age at onset)
621	20	5950652.0	5998977.0	MCM8	Menopause (age at onset)
622	20	5950652.0	5998977.0	MCM8	Preeclampsia
623	20	5950652.0	5998977.0	MCM8	Response to tocilizumab in rheumatoid arthritis
624	20	5950652.0	5998977.0	MCM8	Schizophrenia
625	20	35226654.0	35277000.0	MMP24	Attention deficit hyperactivity disorder
626	20	35201745.0	35278131.0	MMP24OS	Attention deficit hyperactivity disorder
627	20	35201745.0	35278131.0	MMP24OS	Ulcerative colitis
628	20	46008908.0	46016561.0	MMP9	Mild influenza (H1N1) infection
629	20	62796453.0	62801738.0	MRGBP	Subjective well-being
630	20	37101226.0	37179588.0	MROH8	Hippocampal atrophy
631	20	37101226.0	37179588.0	MROH8	Information processing speed
632	20	43667019.0	43716496.0	MYBL2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
633	20	34975403.0	35002437.0	MYH7B	Anticoagulant levels
634	20	34975403.0	35002437.0	MYH7B	Congenital left-sided heart lesions
635	20	34975403.0	35002437.0	MYH7B	Melanoma
636	20	31819308.0	31834689.0	MYLK2	Platelet count
637	20	31819308.0	31834689.0	MYLK2	Plateletcrit
638	20	64151791.0	64242253.0	MYT1	Colorectal cancer
639	20	64151791.0	64242253.0	MYT1	Restless legs syndrome
640	20	23374519.0	23421519.0	NAPB	Facial morphology (factor 15, philtrum width)
641	20	47501902.0	47656877.0	NCOA3	Response to treatment for acute lymphoblastic leukemia
642	20	47501902.0	47656877.0	NCOA3	Systemic lupus erythematosus
643	20	46060985.0	46089952.0	NCOA5	Multiple sclerosis
644	20	34689097.0	34825649.0	NCOA6	Coronary artery disease
645	20	34689097.0	34825649.0	NCOA6	Diisocyanate-induced asthma
646	20	34689097.0	34825649.0	NCOA6	Glomerular filtration rate (creatinine)
647	20	34689097.0	34825649.0	NCOA6	Hip circumference adjusted for BMI
648	20	58981208.0	58995133.0	NELFCD	Response to diuretic therapy in hypertension
649	20	51386957.0	51562831.0	NFATC2	Allergic disease (asthma, hay fever or eczema)
650	20	51386957.0	51562831.0	NFATC2	Amyotrophic lateral sclerosis (sporadic)
651	20	51386957.0	51562831.0	NFATC2	Asparaginase hypersensitivity in acute lymphoblastic leukemia
652	20	51386957.0	51562831.0	NFATC2	Eosinophil percentage of white cells
653	20	51386957.0	51562831.0	NFATC2	Lobe attachment (rater-scored or self-reported)
654	20	51386957.0	51562831.0	NFATC2	Self-reported allergy
655	20	51386957.0	51562831.0	NFATC2	Sitting height ratio
656	20	51386957.0	51562831.0	NFATC2	Sum eosinophil basophil counts
657	20	51386957.0	51562831.0	NFATC2	White matter microstructure in first episode schizophrenia (right anterior cingulate cortex)
658	20	35668055.0	35699359.0	NFS1	Response to paliperidone in schizophrenia (Multivariate)
659	20	35668055.0	35699359.0	NFS1	Response to paliperidone in schizophrenia (PANSS score)
660	20	63240784.0	63272694.0	NKAIN4	Cardiovascular disease risk factors
661	20	32443059.0	32585074.0	NOL4L	Age at first birth
662	20	32443059.0	32585074.0	NOL4L	Chronic obstructive pulmonary disease
663	20	32443059.0	32585074.0	NOL4L	High light scatter reticulocyte count
664	20	32443059.0	32585074.0	NOL4L	High light scatter reticulocyte percentage of red cells
665	20	32443059.0	32585074.0	NOL4L	Immature fraction of reticulocytes
666	20	32443059.0	32585074.0	NOL4L	Mean corpuscular hemoglobin
667	20	32443059.0	32585074.0	NOL4L	Mean corpuscular volume
668	20	32443059.0	32585074.0	NOL4L	Monocyte count
669	20	32443059.0	32585074.0	NOL4L	Red blood cell count
670	20	32443059.0	32585074.0	NOL4L	Red cell distribution width
671	20	64105820.0	64107171.0	NPBWR2	Body mass index
672	20	58689131.0	58719238.0	NPEPL1	Post bronchodilator FEV1/FVC ratio
673	20	346782.0	359660.0	NRSN2	Amyotrophic lateral sclerosis (sporadic)
674	20	346782.0	359660.0	NRSN2	Anticoagulant levels
675	20	346782.0	359660.0	NRSN2	Attention deficit hyperactivity disorder
676	20	346782.0	359660.0	NRSN2	Blood protein levels
677	20	346782.0	359660.0	NRSN2	Breast cancer
678	20	346782.0	359660.0	NRSN2	Cholesterol, total
679	20	346782.0	359660.0	NRSN2	Congenital left-sided heart lesions
680	20	346782.0	359660.0	NRSN2	Coronary artery disease
681	20	346782.0	359660.0	NRSN2	D-dimer levels
682	20	346782.0	359660.0	NRSN2	Developmental dysplasia of the hip
683	20	346782.0	359660.0	NRSN2	Diisocyanate-induced asthma
684	20	346782.0	359660.0	NRSN2	Factor VII levels
685	20	346782.0	359660.0	NRSN2	Freckling
686	20	346782.0	359660.0	NRSN2	Glomerular filtration rate (creatinine)
687	20	346782.0	359660.0	NRSN2	Height
688	20	346782.0	359660.0	NRSN2	Hemostatic factors and hematological phenotypes
689	20	346782.0	359660.0	NRSN2	Hip circumference
690	20	346782.0	359660.0	NRSN2	Hip circumference adjusted for BMI
691	20	346782.0	359660.0	NRSN2	Infant length
692	20	346782.0	359660.0	NRSN2	Joint mobility (Beighton score)
693	20	346782.0	359660.0	NRSN2	Lobe attachment (rater-scored or self-reported)
694	20	346782.0	359660.0	NRSN2	Melanoma
695	20	346782.0	359660.0	NRSN2	Migraine - clinic-based
696	20	346782.0	359660.0	NRSN2	Neuroticism
697	20	346782.0	359660.0	NRSN2	Protein C levels
698	20	346782.0	359660.0	NRSN2	Prothrombin time
699	20	346782.0	359660.0	NRSN2	QRS complex (Cornell)
700	20	346782.0	359660.0	NRSN2	QRS interval (sulfonylurea treatment interaction)
701	20	346782.0	359660.0	NRSN2	Response to paliperidone in schizophrenia (Multivariate)
702	20	346782.0	359660.0	NRSN2	Response to paliperidone in schizophrenia (PANSS score)
703	20	346782.0	359660.0	NRSN2	Spine bone size
704	20	346782.0	359660.0	NRSN2	Thrombosis
705	20	346782.0	359660.0	NRSN2	Total cholesterol levels
706	20	346782.0	359660.0	NRSN2	Triglycerides
707	20	346782.0	359660.0	NRSN2	Ulcerative colitis
708	20	346782.0	359660.0	NRSN2	Venous thromboembolism
709	20	346782.0	359660.0	NRSN2	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
710	20	346782.0	359660.0	NRSN2	Waist-to-hip ratio adjusted for BMI in active individuals
711	20	346782.0	359660.0	NRSN2	Waist-to-hip ratio adjusted for body mass index
712	20	1442162.0	1473842.0	NSFL1C	Intelligence (multi-trait analysis)
713	20	64080173.0	64100643.0	OPRL1	LDL peak particle diameter (total fat intake interaction)
714	20	44196496.0	44210791.0	OSER1	Granulocyte percentage of myeloid white cells
715	20	16748358.0	16770062.0	OTOR	Post-traumatic stress disorder (asjusted for relatedness)
716	20	9537389.0	9839041.0	PAK5	3-hydroxypropylmercapturic acid levels in smokers
717	20	9537389.0	9839041.0	PAK5	Growth-regulated protein alpha levels
718	20	9537389.0	9839041.0	PAK5	Obesity-related traits
719	20	9537389.0	9839041.0	PAK5	Psoriasis
720	20	3888839.0	3929882.0	PANK2	Alcohol and nicotine co-dependence
721	20	3888839.0	3929882.0	PANK2	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis
722	20	3888839.0	3929882.0	PANK2	Colonoscopy-negative controls vs population controls
723	20	3888839.0	3929882.0	PANK2	Dialysis-related mortality
724	20	3888839.0	3929882.0	PANK2	Huntington's disease progression
725	20	3888839.0	3929882.0	PANK2	Intraocular pressure
726	20	3888839.0	3929882.0	PANK2	Itch intensity from mosquito bite adjusted by bite size
727	20	3888839.0	3929882.0	PANK2	Measles
728	20	3888839.0	3929882.0	PANK2	Post bronchodilator FEV1/FVC ratio
729	20	3888839.0	3929882.0	PANK2	Response to amphetamines
730	20	45934628.0	45948023.0	PCIF1	Abdominal aortic aneurysm
731	20	45934628.0	45948023.0	PCIF1	Gut microbiota (functional units)
732	20	45934628.0	45948023.0	PCIF1	HDL cholesterol
733	20	45934628.0	45948023.0	PCIF1	Mean corpuscular hemoglobin
734	20	45934628.0	45948023.0	PCIF1	Mean corpuscular volume
735	20	45934628.0	45948023.0	PCIF1	Triglycerides
736	20	57561080.0	57568112.0	PCK1	Emphysema imaging phenotypes
737	20	57561080.0	57568112.0	PCK1	Prudent dietary pattern
738	20	5114953.0	5126626.0	PCNA	Tuberculosis
739	20	17226107.0	17484578.0	PCSK2	Biochemical measures
740	20	17226107.0	17484578.0	PCSK2	Dialysis-related mortality
741	20	17226107.0	17484578.0	PCSK2	Gut microbiome composition (summer)
742	20	17226107.0	17484578.0	PCSK2	Interleukin-1-beta levels
743	20	17226107.0	17484578.0	PCSK2	Obesity-related traits
744	20	17226107.0	17484578.0	PCSK2	Preschool internalizing problems
745	20	1978757.0	1994285.0	PDYN	Bipolar disorder (body mass index interaction)
746	20	1978757.0	1994285.0	PDYN	Bipolar disorder and schizophrenia
747	20	1978757.0	1994285.0	PDYN	Obesity-related traits
748	20	1978757.0	1994285.0	PDYN	Platelet distribution width
749	20	1978757.0	1994285.0	PDYN	Verbal declarative memory
750	20	54207847.0	54228052.0	PFDN4	Obesity-related traits
751	20	59577509.0	59847711.0	PHACTR3	Breast cancer
752	20	59577509.0	59847711.0	PHACTR3	HIV-1 viral setpoint
753	20	59577509.0	59847711.0	PHACTR3	Intelligence (multi-trait analysis)
754	20	59577509.0	59847711.0	PHACTR3	Menarche and menopause (age at onset)
755	20	59577509.0	59847711.0	PHACTR3	Menopause (age at onset)
756	20	59577509.0	59847711.0	PHACTR3	Preeclampsia
757	20	59577509.0	59847711.0	PHACTR3	Response to tocilizumab in rheumatoid arthritis
758	20	59577509.0	59847711.0	PHACTR3	Schizophrenia
759	20	35771974.0	35950381.0	PHF20	Breast cancer
760	20	35771974.0	35950381.0	PHF20	Height
761	20	35771974.0	35950381.0	PHF20	Migraine - clinic-based
762	20	35771974.0	35950381.0	PHF20	Response to paliperidone in schizophrenia (Multivariate)
763	20	35771974.0	35950381.0	PHF20	Response to paliperidone in schizophrenia (PANSS score)
764	20	34560542.0	34698790.0	PIGU	Glomerular filtration rate (creatinine)
765	20	34560542.0	34698790.0	PIGU	Melanoma
766	20	8077251.0	8968360.0	PLCB1	3-hydroxy-1-methylpropylmercapturic acid levels in smokers
767	20	8077251.0	8968360.0	PLCB1	3-hydroxypropylmercapturic acid levels in smokers
768	20	8077251.0	8968360.0	PLCB1	Chronic kidney disease
769	20	8077251.0	8968360.0	PLCB1	Cognitive performance
770	20	8077251.0	8968360.0	PLCB1	Daytime sleep phenotypes
771	20	8077251.0	8968360.0	PLCB1	Diastolic blood pressure
772	20	8077251.0	8968360.0	PLCB1	Estradiol plasma levels (breast cancer)
773	20	8077251.0	8968360.0	PLCB1	Lymphocyte counts
774	20	8077251.0	8968360.0	PLCB1	Monocyte count
775	20	8077251.0	8968360.0	PLCB1	Obesity-related traits
776	20	8077251.0	8968360.0	PLCB1	Obstructive sleep apnea trait (average respiratory event duration)
777	20	8077251.0	8968360.0	PLCB1	Platelet count
778	20	8077251.0	8968360.0	PLCB1	Platelet distribution width
779	20	8077251.0	8968360.0	PLCB1	Plateletcrit
780	20	8077251.0	8968360.0	PLCB1	Response to irinotecan in non-small-cell lung cancer
781	20	8077251.0	8968360.0	PLCB1	Response to paliperidone in schizophrenia (Multivariate)
782	20	8077251.0	8968360.0	PLCB1	Social communication problems
783	20	8077251.0	8968360.0	PLCB1	Suicide ideation score in major depressive disorder
784	20	8077251.0	8968360.0	PLCB1	White blood cell count
785	20	9068763.0	9481242.0	PLCB4	Initial pursuit acceleration
786	20	9068763.0	9481242.0	PLCB4	Initial pursuit acceleration in psychotic disorders
787	20	9068763.0	9481242.0	PLCB4	Neutrophil count
788	20	9068763.0	9481242.0	PLCB4	Posterior cortical atrophy and Alzheimer's disease
789	20	9068763.0	9481242.0	PLCB4	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)
790	20	9068763.0	9481242.0	PLCB4	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)
791	20	41136960.0	41196801.0	PLCG1	Age-related disease endophenotypes
792	20	41136960.0	41196801.0	PLCG1	Age-related diseases, mortality and associated endophenotypes
793	20	41136960.0	41196801.0	PLCG1	Cholesterol, total
794	20	41136960.0	41196801.0	PLCG1	Coronary artery disease
795	20	41136960.0	41196801.0	PLCG1	Height
796	20	41136960.0	41196801.0	PLCG1	Hemoglobin concentration
797	20	45898621.0	45912155.0	PLTP	Gut microbiota (functional units)
798	20	45898621.0	45912155.0	PLTP	HDL cholesterol
799	20	45898621.0	45912155.0	PLTP	Lipid metabolism phenotypes
800	20	45898621.0	45912155.0	PLTP	Pathological gambling
801	20	57648392.0	57711536.0	PMEPA1	Verbal declarative memory
802	20	57648392.0	57711536.0	PMEPA1	Warfarin maintenance dose
803	20	32207880.0	32238667.0	POFUT1	Chronic obstructive pulmonary disease
804	20	38805705.0	38923024.0	PPP1R16B	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis
805	20	38805705.0	38923024.0	PPP1R16B	Schizophrenia
806	20	59033145.0	59042909.0	PRELID3B	Mean platelet volume
807	20	59033145.0	59042909.0	PRELID3B	Platelet distribution width
808	20	48624252.0	48827883.0	PREX1	Colorectal cancer
809	20	48624252.0	48827883.0	PREX1	Diastolic blood pressure
810	20	48624252.0	48827883.0	PREX1	Intelligence (multi-trait analysis)
811	20	48624252.0	48827883.0	PREX1	Multiple myeloma
812	20	48624252.0	48827883.0	PREX1	Narcolepsy with cataplexy
813	20	48624252.0	48827883.0	PREX1	Tonometry
814	20	4686236.0	4701590.0	PRNP	Creutzfeldt-Jakob disease
815	20	4686236.0	4701590.0	PRNP	Creutzfeldt-Jakob disease (sporadic)
816	20	4686236.0	4701590.0	PRNP	Creutzfeldt-Jakob disease (variant)
817	20	4686236.0	4701590.0	PRNP	Post bronchodilator FEV1/FVC ratio
818	20	4686236.0	4701590.0	PRNP	Prion diseases
819	20	4686236.0	4701590.0	PRNP	Visceral adipose tissue/subcutaneous adipose tissue ratio
820	20	4686236.0	4701590.0	PRNP	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
821	20	4686236.0	4701590.0	PRNP	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
822	20	4686236.0	4701590.0	PRNP	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)
823	20	4686236.0	4701590.0	PRNP	Waist-to-hip ratio adjusted for BMI in active individuals
824	20	4686236.0	4701590.0	PRNP	Waist-to-hip ratio adjusted for body mass index
825	20	35172073.0	35216240.0	PROCR	Amyotrophic lateral sclerosis (sporadic)
826	20	35172073.0	35216240.0	PROCR	Anticoagulant levels
827	20	35172073.0	35216240.0	PROCR	Blood protein levels
828	20	35172073.0	35216240.0	PROCR	Coronary artery disease
829	20	35172073.0	35216240.0	PROCR	D-dimer levels
830	20	35172073.0	35216240.0	PROCR	Factor VII levels
831	20	35172073.0	35216240.0	PROCR	Height
832	20	35172073.0	35216240.0	PROCR	Hemostatic factors and hematological phenotypes
833	20	35172073.0	35216240.0	PROCR	Protein C levels
834	20	35172073.0	35216240.0	PROCR	Thrombosis
835	20	35172073.0	35216240.0	PROCR	Ulcerative colitis
836	20	35172073.0	35216240.0	PROCR	Venous thromboembolism
837	20	5302040.0	5314369.0	PROKR2	Urinary tract infection frequency
838	20	63981135.0	64033100.0	PRPF6	Colorectal cancer
839	20	1113263.0	1189415.0	PSMF1	Angiotensin-converting enzyme inhibitor intolerance
840	20	1113263.0	1189415.0	PSMF1	Breast cancer
841	20	1113263.0	1189415.0	PSMF1	Cardiac hypertrophy
842	20	1113263.0	1189415.0	PSMF1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes
843	20	1113263.0	1189415.0	PSMF1	Gut microbiome composition (summer)
844	20	1113263.0	1189415.0	PSMF1	Night sleep phenotypes
845	20	1113263.0	1189415.0	PSMF1	Relative hand skill
846	20	1113263.0	1189415.0	PSMF1	Response to citalopram treatment
847	20	49503874.0	49568146.0	PTGIS	Schizophrenia
848	20	63528001.0	63537370.0	PTK6	Hair shape
849	20	50510321.0	50585241.0	PTPN1	Hair morphology
850	20	42072752.0	43189970.0	PTPRT	Age-related nuclear cataracts
851	20	42072752.0	43189970.0	PTPRT	Diisocyanate-induced asthma
852	20	42072752.0	43189970.0	PTPRT	Facial morphology (factor 20)
853	20	42072752.0	43189970.0	PTPRT	Fractional exhaled nitric oxide (childhood)
854	20	42072752.0	43189970.0	PTPRT	IgG glycosylation
855	20	42072752.0	43189970.0	PTPRT	Microalbuminuria
856	20	42072752.0	43189970.0	PTPRT	Mononucleosis
857	20	42072752.0	43189970.0	PTPRT	Paneth cell defects in Crohn's disease
858	20	42072752.0	43189970.0	PTPRT	Periodontitis (Mean PAL)
859	20	42072752.0	43189970.0	PTPRT	Preeclampsia
860	20	42072752.0	43189970.0	PTPRT	Problematic alcohol use in trauma-exposed individuals
861	20	42072752.0	43189970.0	PTPRT	Response to paliperidone in schizophrenia (negative Marder score)
862	20	42072752.0	43189970.0	PTPRT	Sense of smell
863	20	42072752.0	43189970.0	PTPRT	Urate levels in obese individuals
864	20	42072752.0	43189970.0	PTPRT	Venous thromboembolism adjusted for sickle cell variant rs77121243-T
865	20	33702754.0	33720319.0	PXMP4	Height
866	20	33702754.0	33720319.0	PXMP4	Post bronchodilator FEV1/FVC ratio
867	20	25248069.0	25298014.0	PYGB	Asymmetrical dimethylarginine levels
868	20	25248069.0	25298014.0	PYGB	Calcium levels
869	20	25248069.0	25298014.0	PYGB	Peripheral arterial disease (traffic-related air pollution interaction)
870	20	44336986.0	44351235.0	R3HDML	Colonoscopy-negative controls vs population controls
871	20	44336986.0	44351235.0	R3HDML	Post bronchodilator FEV1/FVC ratio
872	20	58309696.0	58367507.0	RAB22A	Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer
873	20	1226056.0	1296421.0	RAD21L1	Body mass index (recreational physical activity interaction)
874	20	1226056.0	1296421.0	RAD21L1	Brain structure
875	20	1226056.0	1296421.0	RAD21L1	Cognitive decline rate in late mild cognitive impairment
876	20	1226056.0	1296421.0	RAD21L1	Itch intensity from mosquito bite adjusted by bite size
877	20	1226056.0	1296421.0	RAD21L1	Neuroticism
878	20	1226056.0	1296421.0	RAD21L1	Night sleep phenotypes
879	20	1226056.0	1296421.0	RAD21L1	Response to cytadine analogues (cytosine arabinoside)
880	20	1226056.0	1296421.0	RAD21L1	Tumor necrosis factor alpha levels
881	20	1226056.0	1296421.0	RAD21L1	Vascular brain injury
882	20	20389552.0	20712488.0	RALGAPA2	IgG glycosylation
883	20	20389552.0	20712488.0	RALGAPA2	Post bronchodilator FEV1/FVC ratio
884	20	33993646.0	34108308.0	RALY	Basal cell carcinoma
885	20	33993646.0	34108308.0	RALY	Breast cancer
886	20	33993646.0	34108308.0	RALY	Cancer
887	20	33993646.0	34108308.0	RALY	Cancer (pleiotropy)
888	20	33993646.0	34108308.0	RALY	Cutaneous squamous cell carcinoma
889	20	33993646.0	34108308.0	RALY	Facial pigmentation
890	20	33993646.0	34108308.0	RALY	IFN-related cytopenia
891	20	33993646.0	34108308.0	RALY	Melanoma
892	20	33993646.0	34108308.0	RALY	Skin colour saturation
893	20	33993646.0	34108308.0	RALY	Skin sensitivity to sun
894	20	33993646.0	34108308.0	RALY	Squamous cell carcinoma
895	20	33993646.0	34108308.0	RALY	Vitiligo
896	20	4780023.0	4823645.0	RASSF2	Alcohol consumption
897	20	4780023.0	4823645.0	RASSF2	Cerebrospinal fluid AB1-42 levels
898	20	4780023.0	4823645.0	RASSF2	Nephrotic syndrome (acquired)
899	20	4780023.0	4823645.0	RASSF2	Nucleus accumbens volume in trauma-exposed individuals
900	20	4780023.0	4823645.0	RASSF2	Seasonality
901	20	62410237.0	62427533.0	RBBP8NL	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes
902	20	407498.0	430966.0	RBCK1	3-hydroxypropylmercapturic acid levels in smokers
903	20	407498.0	430966.0	RBCK1	Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction)
904	20	407498.0	430966.0	RBCK1	Age-related disease endophenotypes
905	20	407498.0	430966.0	RBCK1	Age-related diseases, mortality and associated endophenotypes
906	20	407498.0	430966.0	RBCK1	Age-related nuclear cataracts
907	20	407498.0	430966.0	RBCK1	Bone mineral accretion in asthma (oral corticosteroid dose interaction)
908	20	407498.0	430966.0	RBCK1	Cholesterol, total
909	20	407498.0	430966.0	RBCK1	Coronary artery disease
910	20	407498.0	430966.0	RBCK1	Dementia and core Alzheimer's disease neuropathologic changes
911	20	407498.0	430966.0	RBCK1	Diisocyanate-induced asthma
912	20	407498.0	430966.0	RBCK1	Facial morphology (factor 20)
913	20	407498.0	430966.0	RBCK1	Fractional exhaled nitric oxide (childhood)
914	20	407498.0	430966.0	RBCK1	Gastric adenocarcinoma (histologically verified)
915	20	407498.0	430966.0	RBCK1	Height
916	20	407498.0	430966.0	RBCK1	Hemoglobin concentration
917	20	407498.0	430966.0	RBCK1	Hepatitis B
918	20	407498.0	430966.0	RBCK1	High light scatter reticulocyte count
919	20	407498.0	430966.0	RBCK1	High light scatter reticulocyte percentage of red cells
920	20	407498.0	430966.0	RBCK1	Hippocampal atrophy
921	20	407498.0	430966.0	RBCK1	IgG glycosylation
922	20	407498.0	430966.0	RBCK1	Immature fraction of reticulocytes
923	20	407498.0	430966.0	RBCK1	Interleukin-18 levels
924	20	407498.0	430966.0	RBCK1	LDL cholesterol
925	20	407498.0	430966.0	RBCK1	LDL cholesterol levels
926	20	407498.0	430966.0	RBCK1	Left ventricle wall thickness
927	20	407498.0	430966.0	RBCK1	Metabolite levels (HVA-5-HIAA Factor score)
928	20	407498.0	430966.0	RBCK1	Microalbuminuria
929	20	407498.0	430966.0	RBCK1	Mononucleosis
930	20	407498.0	430966.0	RBCK1	Non-response to bupropion and depression
931	20	407498.0	430966.0	RBCK1	Paneth cell defects in Crohn's disease
932	20	407498.0	430966.0	RBCK1	Panic disorder
933	20	407498.0	430966.0	RBCK1	Periodontitis (Mean PAL)
934	20	407498.0	430966.0	RBCK1	Preeclampsia
935	20	407498.0	430966.0	RBCK1	QT interval (ambient particulate matter interaction)
936	20	407498.0	430966.0	RBCK1	Response to paliperidone in schizophrenia (negative Marder score)
937	20	407498.0	430966.0	RBCK1	Resting heart rate
938	20	407498.0	430966.0	RBCK1	Reticulocyte count
939	20	407498.0	430966.0	RBCK1	Reticulocyte fraction of red cells
940	20	407498.0	430966.0	RBCK1	Sense of smell
941	20	407498.0	430966.0	RBCK1	Total cholesterol levels
942	20	407498.0	430966.0	RBCK1	Urate levels in obese individuals
943	20	407498.0	430966.0	RBCK1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T
944	20	407498.0	430966.0	RBCK1	Verbal declarative memory
945	20	36996349.0	37095995.0	RBL1	Height
946	20	57391407.0	57409333.0	RBM38	High light scatter reticulocyte count
947	20	57391407.0	57409333.0	RBM38	Reticulocyte count
948	20	57391407.0	57409333.0	RBM38	Reticulocyte fraction of red cells
949	20	19886521.0	20002457.0	RIN2	Platelet distribution width
950	20	49936336.0	49953892.0	RNF114	Inflammatory skin disease
951	20	49936336.0	49953892.0	RNF114	Psoriasis
952	20	49936336.0	49953892.0	RNF114	Psoriasis vulgaris
953	20	3927309.0	4015582.0	RNF24	Chin dimples
954	20	3927309.0	4015582.0	RNF24	Cleft lip with or without cleft palate
955	20	3927309.0	4015582.0	RNF24	Cognitive decline rate in late mild cognitive impairment
956	20	3927309.0	4015582.0	RNF24	Cytomegalovirus antibody response
957	20	3927309.0	4015582.0	RNF24	Dupuytren's disease
958	20	3927309.0	4015582.0	RNF24	Estradiol levels
959	20	3927309.0	4015582.0	RNF24	Granulocyte percentage of myeloid white cells
960	20	3927309.0	4015582.0	RNF24	Height
961	20	3927309.0	4015582.0	RNF24	High light scatter reticulocyte count
962	20	3927309.0	4015582.0	RNF24	High light scatter reticulocyte percentage of red cells
963	20	3927309.0	4015582.0	RNF24	Idiopathic osteonecrosis of the femoral head
964	20	3927309.0	4015582.0	RNF24	Immature fraction of reticulocytes
965	20	3927309.0	4015582.0	RNF24	Interleukin-17 levels
966	20	3927309.0	4015582.0	RNF24	Interleukin-4 levels
967	20	3927309.0	4015582.0	RNF24	Intraocular pressure
968	20	3927309.0	4015582.0	RNF24	Mean corpuscular volume
969	20	3927309.0	4015582.0	RNF24	Monocyte percentage of white cells
970	20	3927309.0	4015582.0	RNF24	Multiple myeloma
971	20	3927309.0	4015582.0	RNF24	Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury)
972	20	3927309.0	4015582.0	RNF24	Nose size
973	20	3927309.0	4015582.0	RNF24	Obesity-related traits
974	20	3927309.0	4015582.0	RNF24	Platelet-derived growth factor BB levels
975	20	3927309.0	4015582.0	RNF24	Response to antidepressants in depression
976	20	3927309.0	4015582.0	RNF24	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)
977	20	3927309.0	4015582.0	RNF24	Reticulocyte count
978	20	3927309.0	4015582.0	RNF24	Reticulocyte fraction of red cells
979	20	3927309.0	4015582.0	RNF24	Schizophrenia
980	20	3927309.0	4015582.0	RNF24	Telomere length
981	20	37178410.0	37241623.0	RPN2	Hippocampal atrophy
982	20	37178410.0	37241623.0	RPN2	Initial pursuit acceleration in psychotic disorders
983	20	38033546.0	38127780.0	RPRD1B	Skin pigmentation
984	20	17613678.0	17682295.0	RRBP1	Coronary artery disease
985	20	63657810.0	63696253.0	RTEL1	Allergic disease (asthma, hay fever or eczema)
986	20	63657810.0	63696253.0	RTEL1	Atopic dermatitis
987	20	63657810.0	63696253.0	RTEL1	Dental caries
988	20	63657810.0	63696253.0	RTEL1	Glioblastoma
989	20	63657810.0	63696253.0	RTEL1	Glioma
990	20	63657810.0	63696253.0	RTEL1	Glioma (high-grade)
991	20	63657810.0	63696253.0	RTEL1	Non-glioblastoma glioma
992	20	63657810.0	63696253.0	RTEL1	Plateletcrit
993	20	63657810.0	63696253.0	RTEL1	Telomere length
994	20	63657810.0	63696253.0	RTEL1	Ulcerative colitis
995	20	51782331.0	51802520.0	SALL4	Nonsyndromic cleft lip with cleft palate
996	20	63974113.0	63980008.0	SAMD10	Tonsillectomy
997	20	35953617.0	35959472.0	SCAND1	Hip circumference adjusted for BMI
998	20	661596.0	676179.0	SCRT2	Body mass index
999	20	661596.0	676179.0	SCRT2	Colorectal cancer
1000	20	661596.0	676179.0	SCRT2	Height
1001	20	661596.0	676179.0	SCRT2	Lung function (FVC)
1002	20	661596.0	676179.0	SCRT2	Sitting height ratio
1003	20	661596.0	676179.0	SCRT2	Waist circumference adjusted for BMI (adjusted for smoking behaviour)
1004	20	661596.0	676179.0	SCRT2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)
1005	20	661596.0	676179.0	SCRT2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
1006	20	661596.0	676179.0	SCRT2	Waist circumference adjusted for BMI in active individuals
1007	20	661596.0	676179.0	SCRT2	Waist circumference adjusted for BMI in non-smokers
1008	20	661596.0	676179.0	SCRT2	Waist circumference adjusted for body mass index
1009	20	661596.0	676179.0	SCRT2	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)
1010	20	661596.0	676179.0	SCRT2	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
1011	20	661596.0	676179.0	SCRT2	Waist-to-hip ratio adjusted for body mass index
1012	20	1309909.0	1329239.0	SDCBP2	Body mass index (alcohol intake interaction)
1013	20	1309909.0	1329239.0	SDCBP2	Metabolite levels  (X-11787)
1014	20	1309909.0	1329239.0	SDCBP2	Night sleep phenotypes
1015	20	1309909.0	1329239.0	SDCBP2	Personality traits in bipolar disorder
1016	20	1309909.0	1329239.0	SDCBP2	Survival in colon cancer
1017	20	3686970.0	3707128.0	SIGLEC1	Height
1018	20	3686970.0	3707128.0	SIGLEC1	Red cell distribution width
1019	20	1894167.0	1940592.0	SIRPA	Alcoholic chronic pancreatitis
1020	20	1894167.0	1940592.0	SIRPA	Basophil percentage of granulocytes
1021	20	1894167.0	1940592.0	SIRPA	Daytime sleepiness
1022	20	1894167.0	1940592.0	SIRPA	Mean platelet volume
1023	20	1894167.0	1940592.0	SIRPA	Psychosis (atypical)
1024	20	1894167.0	1940592.0	SIRPA	Pulmonary function decline
1025	20	1894167.0	1940592.0	SIRPA	QT interval (sulfonylurea treatment interaction)
1026	20	1894167.0	1940592.0	SIRPA	Response to citalopram or escitalopram and depression
1027	20	1563521.0	1620061.0	SIRPB1	Body mass index
1028	20	1563521.0	1620061.0	SIRPB1	Brain connectivity
1029	20	1563521.0	1620061.0	SIRPB1	Endometriosis
1030	20	1563521.0	1620061.0	SIRPB1	Epstein-Barr virus copy number in lymphoblastoid cell lines
1031	20	1563521.0	1620061.0	SIRPB1	Presence of antiphospholipid antibodies
1032	20	1563521.0	1620061.0	SIRPB1	TRAIL levels
1033	20	1563521.0	1620061.0	SIRPB1	Thyroid-associated orbitopathy in graves' disease
1034	20	1563521.0	1620061.0	SIRPB1	Yu-Zhi constitution type in type 2 diabetes
1035	20	1470741.0	1491587.0	SIRPB2	Autism
1036	20	1470741.0	1491587.0	SIRPB2	Circulating myeloperoxidase levels (serum)
1037	20	1470741.0	1491587.0	SIRPB2	Intelligence (multi-trait analysis)
1038	20	1470741.0	1491587.0	SIRPB2	Presence of antiphospholipid antibodies
1039	20	1534251.0	1558843.0	SIRPD	Coronary artery aneurysm in Kawasaki disease
1040	20	1534251.0	1558843.0	SIRPD	Male fertility
1041	20	1534251.0	1558843.0	SIRPD	Mean platelet volume
1042	20	1534251.0	1558843.0	SIRPD	Obesity (extreme)
1043	20	1534251.0	1558843.0	SIRPD	Platelet distribution width
1044	20	1534251.0	1558843.0	SIRPD	Plateletcrit
1045	20	1629152.0	1657779.0	SIRPG	Emphysema imaging phenotypes
1046	20	1629152.0	1657779.0	SIRPG	Ileal carcinoids
1047	20	1629152.0	1657779.0	SIRPG	Post bronchodilator FEV1/FVC ratio
1048	20	1629152.0	1657779.0	SIRPG	Response to taxane treatment (docetaxel)
1049	20	1629152.0	1657779.0	SIRPG	Type 1 diabetes
1050	20	46557823.0	46684467.0	SLC13A3	Brain volume in infants (white matter)
1051	20	46557823.0	46684467.0	SLC13A3	Chronic kidney disease
1052	20	46557823.0	46684467.0	SLC13A3	Glomerular filtration rate
1053	20	46557823.0	46684467.0	SLC13A3	Gout
1054	20	4852356.0	5010293.0	SLC23A2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
1055	20	4852356.0	5010293.0	SLC23A2	Anger
1056	20	4852356.0	5010293.0	SLC23A2	Cognitive ability
1057	20	4852356.0	5010293.0	SLC23A2	Cognitive ability (multi-trait analysis)
1058	20	4852356.0	5010293.0	SLC23A2	Colonoscopy-negative controls vs population controls
1059	20	4852356.0	5010293.0	SLC23A2	Colorectal cancer
1060	20	4852356.0	5010293.0	SLC23A2	Coronary artery disease
1061	20	4852356.0	5010293.0	SLC23A2	Depression
1062	20	4852356.0	5010293.0	SLC23A2	Diastolic blood pressure
1063	20	4852356.0	5010293.0	SLC23A2	Educational attainment (years of education)
1064	20	4852356.0	5010293.0	SLC23A2	Gut microbiota (beta diversity)
1065	20	4852356.0	5010293.0	SLC23A2	Height
1066	20	4852356.0	5010293.0	SLC23A2	Hepatitis B
1067	20	4852356.0	5010293.0	SLC23A2	Infant length
1068	20	4852356.0	5010293.0	SLC23A2	Inflammatory skin disease
1069	20	4852356.0	5010293.0	SLC23A2	Intelligence
1070	20	4852356.0	5010293.0	SLC23A2	Intelligence (multi-trait analysis)
1071	20	4852356.0	5010293.0	SLC23A2	Life satisfaction
1072	20	4852356.0	5010293.0	SLC23A2	Multiple myeloma
1073	20	4852356.0	5010293.0	SLC23A2	Narcolepsy with cataplexy
1074	20	4852356.0	5010293.0	SLC23A2	Non-response to citalopram or escitalopram and depression
1075	20	4852356.0	5010293.0	SLC23A2	Obesity-related traits
1076	20	4852356.0	5010293.0	SLC23A2	Palmitic acid (16:0) levels
1077	20	4852356.0	5010293.0	SLC23A2	Positive affect
1078	20	4852356.0	5010293.0	SLC23A2	Psoriasis
1079	20	4852356.0	5010293.0	SLC23A2	Psoriasis vulgaris
1080	20	4852356.0	5010293.0	SLC23A2	QT interval
1081	20	4852356.0	5010293.0	SLC23A2	Schizophrenia
1082	20	4852356.0	5010293.0	SLC23A2	Subjective well-being
1083	20	4852356.0	5010293.0	SLC23A2	Systemic lupus erythematosus
1084	20	4852356.0	5010293.0	SLC23A2	Tonometry
1085	20	4852356.0	5010293.0	SLC23A2	Urate levels in obese individuals
1086	20	4852356.0	5010293.0	SLC23A2	Waist circumference adjusted for BMI (adjusted for smoking behaviour)
1087	20	4852356.0	5010293.0	SLC23A2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
1088	20	4852356.0	5010293.0	SLC23A2	Waist circumference adjusted for BMI in non-smokers
1089	20	4852356.0	5010293.0	SLC23A2	White matter hyperintensity burden
1090	20	19212646.0	19722937.0	SLC24A3	Age at smoking initiation in chronic obstructive pulmonary disease
1091	20	19212646.0	19722937.0	SLC24A3	Aortic root size
1092	20	19212646.0	19722937.0	SLC24A3	Basophil percentage of granulocytes
1093	20	19212646.0	19722937.0	SLC24A3	Daytime sleepiness
1094	20	19212646.0	19722937.0	SLC24A3	Liver enzyme levels (alanine transaminase)
1095	20	19212646.0	19722937.0	SLC24A3	Lymphocyte counts
1096	20	19212646.0	19722937.0	SLC24A3	Lymphocyte percentage of white cells
1097	20	19212646.0	19722937.0	SLC24A3	Matrix metalloproteinase levels
1098	20	19212646.0	19722937.0	SLC24A3	Mean platelet volume
1099	20	19212646.0	19722937.0	SLC24A3	Migraine
1100	20	19212646.0	19722937.0	SLC24A3	Neutrophil percentage of white cells
1101	20	19212646.0	19722937.0	SLC24A3	Peripheral arterial disease (traffic-related air pollution interaction)
1102	20	19212646.0	19722937.0	SLC24A3	Platelet count
1103	20	19212646.0	19722937.0	SLC24A3	Platelet distribution width
1104	20	19212646.0	19722937.0	SLC24A3	Plateletcrit
1105	20	19212646.0	19722937.0	SLC24A3	Psychosis (atypical)
1106	20	19212646.0	19722937.0	SLC24A3	Pulmonary function decline
1107	20	19212646.0	19722937.0	SLC24A3	Pulse pressure
1108	20	19212646.0	19722937.0	SLC24A3	QT interval (sulfonylurea treatment interaction)
1109	20	19212646.0	19722937.0	SLC24A3	White blood cell count (basophil)
1110	20	3227417.0	3239190.0	SLC4A11	Granulocyte percentage of myeloid white cells
1111	20	3227417.0	3239190.0	SLC4A11	Monocyte percentage of white cells
1112	20	760080.0	776015.0	SLC52A3	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)
1113	20	49812713.0	49892242.0	SLC9A8	Gut microbiota (beta diversity)
1114	20	62642445.0	62685785.0	SLCO4A1	Menopause (age at onset)
1115	20	10435303.0	10636829.0	SLX4IP	Body mass index (change over time) in chronic obstructive pulmonary disease
1116	20	10435303.0	10636829.0	SLX4IP	Fasting blood glucose adjusted for BMI
1117	20	4120980.0	4187747.0	SMOX	Age-related disease endophenotypes
1118	20	4120980.0	4187747.0	SMOX	Age-related diseases, mortality and associated endophenotypes
1119	20	4120980.0	4187747.0	SMOX	Bone mineral accretion in asthma (oral corticosteroid dose interaction)
1120	20	4120980.0	4187747.0	SMOX	Coronary artery disease
1121	20	4120980.0	4187747.0	SMOX	Dementia and core Alzheimer's disease neuropathologic changes
1122	20	4120980.0	4187747.0	SMOX	Gastric adenocarcinoma (histologically verified)
1123	20	4120980.0	4187747.0	SMOX	Height
1124	20	4120980.0	4187747.0	SMOX	Hepatitis B
1125	20	4120980.0	4187747.0	SMOX	High light scatter reticulocyte count
1126	20	4120980.0	4187747.0	SMOX	High light scatter reticulocyte percentage of red cells
1127	20	4120980.0	4187747.0	SMOX	Hippocampal atrophy
1128	20	4120980.0	4187747.0	SMOX	Immature fraction of reticulocytes
1129	20	4120980.0	4187747.0	SMOX	Left ventricle wall thickness
1130	20	4120980.0	4187747.0	SMOX	Reticulocyte count
1131	20	4120980.0	4187747.0	SMOX	Reticulocyte fraction of red cells
1132	20	4120980.0	4187747.0	SMOX	Verbal declarative memory
1133	20	10218830.0	10307418.0	SNAP25	Diisocyanate-induced asthma
1134	20	10218830.0	10307418.0	SNAP25	Educational attainment
1135	20	10218830.0	10307418.0	SNAP25	Mononucleosis
1136	20	1266316.0	1309328.0	SNPH	Blood metabolite levels
1137	20	1266316.0	1309328.0	SNPH	Blood metabolite ratios
1138	20	1266316.0	1309328.0	SNPH	Body mass index (recreational physical activity interaction)
1139	20	1266316.0	1309328.0	SNPH	Brain structure
1140	20	1266316.0	1309328.0	SNPH	Daytime sleep phenotypes
1141	20	1266316.0	1309328.0	SNPH	Glycerophospholipid levels
1142	20	1266316.0	1309328.0	SNPH	LDL cholesterol
1143	20	1266316.0	1309328.0	SNPH	LDL cholesterol levels
1144	20	1266316.0	1309328.0	SNPH	Neuroticism
1145	20	1266316.0	1309328.0	SNPH	Parental extreme longevity (95 years and older)
1146	20	1266316.0	1309328.0	SNPH	Sphingolipid levels
1147	20	1266316.0	1309328.0	SNPH	Very long-chain saturated fatty acid levels (fatty acid 20:0)
1148	20	1266316.0	1309328.0	SNPH	Very long-chain saturated fatty acid levels (fatty acid 24:0)
1149	20	16729961.0	16742563.0	SNRPB2	Plateletcrit
1150	20	17941597.0	17968980.0	SNX5	Mean platelet volume
1151	20	325595.0	330224.0	SOX12	Attention deficit hyperactivity disorder (combined symptoms)
1152	20	325595.0	330224.0	SOX12	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
1153	20	325595.0	330224.0	SOX12	Basophil percentage of granulocytes
1154	20	325595.0	330224.0	SOX12	Basophil percentage of white cells
1155	20	325595.0	330224.0	SOX12	Birth weight
1156	20	325595.0	330224.0	SOX12	Granulocyte percentage of myeloid white cells
1157	20	325595.0	330224.0	SOX12	Inflammatory bowel disease
1158	20	325595.0	330224.0	SOX12	Iron status biomarkers (iron levels)
1159	20	325595.0	330224.0	SOX12	Iron status biomarkers (transferrin saturation)
1160	20	325595.0	330224.0	SOX12	Lymphocyte counts
1161	20	325595.0	330224.0	SOX12	Lymphocyte percentage of white cells
1162	20	325595.0	330224.0	SOX12	Monocyte count
1163	20	325595.0	330224.0	SOX12	Monocyte percentage of white cells
1164	20	325595.0	330224.0	SOX12	Red cell distribution width
1165	20	325595.0	330224.0	SOX12	Subjective well-being
1166	20	325595.0	330224.0	SOX12	Type 1 diabetes nephropathy
1167	20	325595.0	330224.0	SOX12	Type 2 diabetes
1168	20	325595.0	330224.0	SOX12	Ulcerative colitis
1169	20	325595.0	330224.0	SOX12	White blood cell count (basophil)
1170	20	49903391.0	49915508.0	SPATA2	Psoriasis
1171	20	13008979.0	13169103.0	SPTLC3	Body mass index (alcohol intake interaction)
1172	20	13008979.0	13169103.0	SPTLC3	Daytime sleep phenotypes
1173	20	13008979.0	13169103.0	SPTLC3	Personality traits in bipolar disorder
1174	20	37344685.0	37406050.0	SRC	Squamous cell carcinoma
1175	20	646615.0	653370.0	SRXN1	Height
1176	20	646615.0	653370.0	SRXN1	Hip circumference adjusted for BMI
1177	20	646615.0	653370.0	SRXN1	QRS complex (Cornell)
1178	20	49113339.0	49188367.0	STAU1	Cognitive ability
1179	20	49113339.0	49188367.0	STAU1	Cognitive ability (multi-trait analysis)
1180	20	49113339.0	49188367.0	STAU1	Height
1181	20	49113339.0	49188367.0	STAU1	Intelligence (multi-trait analysis)
1182	20	2101611.0	2177038.0	STK35	Body mass index
1183	20	2101611.0	2177038.0	STK35	Cannabis dependence symptom count
1184	20	2101611.0	2177038.0	STK35	Facial morphology (factor 7, width of cartilaginous portion of nose)
1185	20	2101611.0	2177038.0	STK35	Height
1186	20	2101611.0	2177038.0	STK35	Hirschsprung disease
1187	20	2101611.0	2177038.0	STK35	Lupus nephritis in systemic lupus erythematosus
1188	20	2101611.0	2177038.0	STK35	Mean corpuscular hemoglobin
1189	20	2101611.0	2177038.0	STK35	Nose morphology
1190	20	2101611.0	2177038.0	STK35	Peanut allergy
1191	20	2101611.0	2177038.0	STK35	Pediatric bone mineral content (radius)
1192	20	2101611.0	2177038.0	STK35	Sulfasalazine-induced agranulocytosis
1193	20	44966474.0	45079959.0	STK4	Positive affect
1194	20	44966474.0	45079959.0	STK4	Schizophrenia
1195	20	47656348.0	47786616.0	SULF2	Attention deficit hyperactivity disorder (time to onset)
1196	20	47656348.0	47786616.0	SULF2	Post bronchodilator FEV1/FVC ratio in COPD
1197	20	61953469.0	62065810.0	TAF4	Body mass index
1198	20	61953469.0	62065810.0	TAF4	Smooth-surface caries
1199	20	13389392.0	13638940.0	TASP1	Chin dimples
1200	20	13389392.0	13638940.0	TASP1	Tonsillectomy
1201	20	435480.0	462553.0	TBC1D20	3-hydroxy-1-methylpropylmercapturic acid levels in smokers
1202	20	435480.0	462553.0	TBC1D20	3-hydroxypropylmercapturic acid levels in smokers
1203	20	435480.0	462553.0	TBC1D20	Abdominal aortic aneurysm
1204	20	435480.0	462553.0	TBC1D20	Advanced age-related macular degeneration
1205	20	435480.0	462553.0	TBC1D20	Asthma
1206	20	435480.0	462553.0	TBC1D20	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
1207	20	435480.0	462553.0	TBC1D20	Bacterial meningitis
1208	20	435480.0	462553.0	TBC1D20	Bipolar disorder
1209	20	435480.0	462553.0	TBC1D20	Blood protein levels
1210	20	435480.0	462553.0	TBC1D20	Brain structure
1211	20	435480.0	462553.0	TBC1D20	C-reactive protein
1212	20	435480.0	462553.0	TBC1D20	C-reactive protein levels
1213	20	435480.0	462553.0	TBC1D20	C-reactive protein levels or HDL-cholesterol levels (pleiotropy)
1214	20	435480.0	462553.0	TBC1D20	C-reactive protein levels or LDL-cholesterol levels (pleiotropy)
1215	20	435480.0	462553.0	TBC1D20	C-reactive protein levels or total cholesterol levels (pleiotropy)
1216	20	435480.0	462553.0	TBC1D20	C-reactive protein levels or triglyceride levels (pleiotropy)
1217	20	435480.0	462553.0	TBC1D20	Cholesterol, total
1218	20	435480.0	462553.0	TBC1D20	Chronic hepatitis B infection
1219	20	435480.0	462553.0	TBC1D20	Clozapine-induced agranulocytosis
1220	20	435480.0	462553.0	TBC1D20	Coenzyme Q10 levels
1221	20	435480.0	462553.0	TBC1D20	Cognitive performance
1222	20	435480.0	462553.0	TBC1D20	Colonoscopy-negative controls vs population controls
1223	20	435480.0	462553.0	TBC1D20	Conduct disorder (symptom count)
1224	20	435480.0	462553.0	TBC1D20	Coronary artery disease
1225	20	435480.0	462553.0	TBC1D20	Crohn's disease
1226	20	435480.0	462553.0	TBC1D20	Current cigarettes per day in chronic obstructive pulmonary disease
1227	20	435480.0	462553.0	TBC1D20	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip)
1228	20	435480.0	462553.0	TBC1D20	Facial morphology (factor 21, depth of nasal alae)
1229	20	435480.0	462553.0	TBC1D20	Fibrinogen levels
1230	20	435480.0	462553.0	TBC1D20	Glomerular filtration rate (creatinine)
1231	20	435480.0	462553.0	TBC1D20	Granulocyte count
1232	20	435480.0	462553.0	TBC1D20	Granulocyte percentage of myeloid white cells
1233	20	435480.0	462553.0	TBC1D20	Gut microbiota (bacterial taxa)
1234	20	435480.0	462553.0	TBC1D20	Gut microbiota (functional units)
1235	20	435480.0	462553.0	TBC1D20	HDL cholesterol
1236	20	435480.0	462553.0	TBC1D20	HDL cholesterol levels
1237	20	435480.0	462553.0	TBC1D20	Hematocrit
1238	20	435480.0	462553.0	TBC1D20	Hemoglobin levels
1239	20	435480.0	462553.0	TBC1D20	IgG glycosylation
1240	20	435480.0	462553.0	TBC1D20	Inflammatory bowel disease
1241	20	435480.0	462553.0	TBC1D20	Intelligence (multi-trait analysis)
1242	20	435480.0	462553.0	TBC1D20	Kawasaki disease
1243	20	435480.0	462553.0	TBC1D20	Late-onset Alzheimer's disease
1244	20	435480.0	462553.0	TBC1D20	Lipid metabolism phenotypes
1245	20	435480.0	462553.0	TBC1D20	Lymphocyte percentage of white cells
1246	20	435480.0	462553.0	TBC1D20	Mean corpuscular hemoglobin
1247	20	435480.0	462553.0	TBC1D20	Mean corpuscular volume
1248	20	435480.0	462553.0	TBC1D20	Mean platelet volume
1249	20	435480.0	462553.0	TBC1D20	Metabolite levels
1250	20	435480.0	462553.0	TBC1D20	Metabolite levels (lipoprotein measures)
1251	20	435480.0	462553.0	TBC1D20	Mild influenza (H1N1) infection
1252	20	435480.0	462553.0	TBC1D20	Monocyte count
1253	20	435480.0	462553.0	TBC1D20	Monocyte percentage of white cells
1254	20	435480.0	462553.0	TBC1D20	Multiple sclerosis
1255	20	435480.0	462553.0	TBC1D20	Myeloid white cell count
1256	20	435480.0	462553.0	TBC1D20	Neutrophil count
1257	20	435480.0	462553.0	TBC1D20	Neutrophil percentage of white cells
1258	20	435480.0	462553.0	TBC1D20	Obesity-related traits
1259	20	435480.0	462553.0	TBC1D20	Pancreatic cancer
1260	20	435480.0	462553.0	TBC1D20	Parental longevity (mother's age at death)
1261	20	435480.0	462553.0	TBC1D20	Pathological gambling
1262	20	435480.0	462553.0	TBC1D20	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)
1263	20	435480.0	462553.0	TBC1D20	Positive affect
1264	20	435480.0	462553.0	TBC1D20	Post bronchodilator FEV1/FVC ratio
1265	20	435480.0	462553.0	TBC1D20	Post bronchodilator FEV1/FVC ratio in COPD
1266	20	435480.0	462553.0	TBC1D20	Psoriasis
1267	20	435480.0	462553.0	TBC1D20	Red blood cell count
1268	20	435480.0	462553.0	TBC1D20	Response to amphetamines
1269	20	435480.0	462553.0	TBC1D20	Rheumatoid arthritis
1270	20	435480.0	462553.0	TBC1D20	Schizophrenia
1271	20	435480.0	462553.0	TBC1D20	Sum basophil neutrophil counts
1272	20	435480.0	462553.0	TBC1D20	Sum neutrophil eosinophil counts
1273	20	435480.0	462553.0	TBC1D20	Tonsillectomy
1274	20	435480.0	462553.0	TBC1D20	Triglyceride levels
1275	20	435480.0	462553.0	TBC1D20	Triglycerides
1276	20	435480.0	462553.0	TBC1D20	Type 2 diabetes
1277	20	435480.0	462553.0	TBC1D20	Ulcerative colitis
1278	20	435480.0	462553.0	TBC1D20	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
1279	20	435480.0	462553.0	TBC1D20	Waist circumference adjusted for BMI (smoking interaction)
1280	20	64049836.0	64072347.0	TCEA2	Diastolic blood pressure
1281	20	64049836.0	64072347.0	TCEA2	Serum thyroid-stimulating hormone levels
1282	20	603797.0	610398.0	TCF15	Abdominal aortic aneurysm
1283	20	603797.0	610398.0	TCF15	Cough in response to angiotensin-converting enzyme inhibitor drugs
1284	20	603797.0	610398.0	TCF15	Menopause (age at onset)
1285	20	603797.0	610398.0	TCF15	Non-alcoholic fatty liver disease histology (other)
1286	20	603797.0	610398.0	TCF15	Survival in colon cancer
1287	20	62841115.0	62861763.0	TCFL5	Obesity-related traits
1288	20	2296001.0	2341078.0	TGM3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)
1289	20	2296001.0	2341078.0	TGM3	Basal cell carcinoma
1290	20	2296001.0	2341078.0	TGM3	Facial morphology (factor 15, philtrum width)
1291	20	2296001.0	2341078.0	TGM3	Inflammatory skin disease
1292	20	2296001.0	2341078.0	TGM3	Liver enzyme levels (alanine transaminase)
1293	20	2296001.0	2341078.0	TGM3	Obesity-related traits
1294	20	2296001.0	2341078.0	TGM3	PR interval in Tripanosoma cruzi seropositivity
1295	20	2296001.0	2341078.0	TGM3	Tuberculosis
1296	20	2296001.0	2341078.0	TGM3	Venous thromboembolism
1297	20	2380908.0	2432753.0	TGM6	3-hydroxypropylmercapturic acid levels in smokers
1298	20	2380908.0	2432753.0	TGM6	Alzheimer's disease (cognitive decline)
1299	20	2380908.0	2432753.0	TGM6	Blood protein levels
1300	20	2380908.0	2432753.0	TGM6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease
1301	20	2380908.0	2432753.0	TGM6	Erectile dysfunction and prostate cancer treatment
1302	20	2380908.0	2432753.0	TGM6	Response to TNF antagonist treatment
1303	20	32109506.0	32167258.0	TM9SF4	Chronic hepatitis C infection
1304	20	32109506.0	32167258.0	TM9SF4	Chronic obstructive pulmonary disease
1305	20	32109506.0	32167258.0	TM9SF4	Inflammatory bowel disease
1306	20	32109506.0	32167258.0	TM9SF4	Ribavirin-induced anemia
1307	20	2536607.0	2641784.0	TMC2	3-hydroxy-1-methylpropylmercapturic acid levels in smokers
1308	20	2536607.0	2641784.0	TMC2	Circulating chromogranin peptide levels
1309	20	2536607.0	2641784.0	TMC2	Colorectal or endometrial cancer
1310	20	2536607.0	2641784.0	TMC2	Obesity-related traits
1311	20	2536607.0	2641784.0	TMC2	Parkinson disease and lewy body pathology
1312	20	2536607.0	2641784.0	TMC2	Red blood cell count
1313	20	2536607.0	2641784.0	TMC2	Systemic lupus erythematosus
1314	20	50118254.0	50153734.0	TMEM189	Granulocyte percentage of myeloid white cells
1315	20	50118254.0	50153734.0	TMEM189	Monocyte percentage of white cells
1316	20	5068232.0	5113103.0	TMEM230	Bipolar disorder
1317	20	5068232.0	5113103.0	TMEM230	Breast cancer
1318	20	5068232.0	5113103.0	TMEM230	Longitudinal change in brain amyloid plaque burden
1319	20	5068232.0	5113103.0	TMEM230	Molar-incisor hypomineralization
1320	20	5068232.0	5113103.0	TMEM230	Prostate cancer
1321	20	5068232.0	5113103.0	TMEM230	QT interval (drug interaction)
1322	20	2816302.0	2820284.0	TMEM239	White matter integrity
1323	20	63696668.0	63698684.0	TNFRSF6B	Atopic dermatitis
1324	20	63696668.0	63698684.0	TNFRSF6B	Crohn's disease
1325	20	63696668.0	63698684.0	TNFRSF6B	Inflammatory bowel disease
1326	20	63696668.0	63698684.0	TNFRSF6B	Ulcerative colitis
1327	20	41028818.0	41124487.0	TOP1	Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction)
1328	20	41028818.0	41124487.0	TOP1	Cholesterol, total
1329	20	41028818.0	41124487.0	TOP1	LDL cholesterol
1330	20	41028818.0	41124487.0	TOP1	LDL cholesterol levels
1331	20	43914864.0	44069616.0	TOX2	Conduct disorder (symptom count)
1332	20	43914864.0	44069616.0	TOX2	IgG glycosylation
1333	20	43914864.0	44069616.0	TOX2	Post bronchodilator FEV1/FVC ratio in COPD
1334	20	43914864.0	44069616.0	TOX2	Red blood cell count
1335	20	362835.0	397559.0	TRIB3	Airway wall thickness
1336	20	362835.0	397559.0	TRIB3	Alcohol and nicotine co-dependence
1337	20	362835.0	397559.0	TRIB3	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis
1338	20	362835.0	397559.0	TRIB3	Antibody status in Tripanosoma cruzi seropositivity
1339	20	362835.0	397559.0	TRIB3	Asthma
1340	20	362835.0	397559.0	TRIB3	Autism spectrum disorder or schizophrenia
1341	20	362835.0	397559.0	TRIB3	Bipolar disorder
1342	20	362835.0	397559.0	TRIB3	Bipolar disorder and schizophrenia
1343	20	362835.0	397559.0	TRIB3	Bone mineral density
1344	20	362835.0	397559.0	TRIB3	Cerebrospinal fluid biomarker levels
1345	20	362835.0	397559.0	TRIB3	Chin dimples
1346	20	362835.0	397559.0	TRIB3	Cognitive decline rate in late mild cognitive impairment
1347	20	362835.0	397559.0	TRIB3	Colonoscopy-negative controls vs population controls
1348	20	362835.0	397559.0	TRIB3	Daytime sleepiness
1349	20	362835.0	397559.0	TRIB3	Dialysis-related mortality
1350	20	362835.0	397559.0	TRIB3	Dupuytren's disease
1351	20	362835.0	397559.0	TRIB3	Estradiol levels
1352	20	362835.0	397559.0	TRIB3	Heart rate
1353	20	362835.0	397559.0	TRIB3	Heart rate variability traits (RMSSD)
1354	20	362835.0	397559.0	TRIB3	Heart rate variability traits (SDNN)
1355	20	362835.0	397559.0	TRIB3	Height
1356	20	362835.0	397559.0	TRIB3	Hepcidin levels
1357	20	362835.0	397559.0	TRIB3	High light scatter reticulocyte count
1358	20	362835.0	397559.0	TRIB3	Hippocampal atrophy
1359	20	362835.0	397559.0	TRIB3	Huntington's disease progression
1360	20	362835.0	397559.0	TRIB3	IgG glycosylation
1361	20	362835.0	397559.0	TRIB3	Information processing speed
1362	20	362835.0	397559.0	TRIB3	Initial pursuit acceleration in psychotic disorders
1363	20	362835.0	397559.0	TRIB3	Interleukin-17 levels
1364	20	362835.0	397559.0	TRIB3	Interleukin-4 levels
1365	20	362835.0	397559.0	TRIB3	Intraocular pressure
1366	20	362835.0	397559.0	TRIB3	Itch intensity from mosquito bite adjusted by bite size
1367	20	362835.0	397559.0	TRIB3	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease
1368	20	362835.0	397559.0	TRIB3	Mean corpuscular volume
1369	20	362835.0	397559.0	TRIB3	Measles
1370	20	362835.0	397559.0	TRIB3	Modified Stumvoll Insulin Sensitivity Index (BMI interaction)
1371	20	362835.0	397559.0	TRIB3	Nose size
1372	20	362835.0	397559.0	TRIB3	Periodontitis (DPAL)
1373	20	362835.0	397559.0	TRIB3	Photic sneeze reflex
1374	20	362835.0	397559.0	TRIB3	Platelet-derived growth factor BB levels
1375	20	362835.0	397559.0	TRIB3	Post bronchodilator FEV1 in COPD
1376	20	362835.0	397559.0	TRIB3	Post bronchodilator FEV1/FVC ratio
1377	20	362835.0	397559.0	TRIB3	Red cell distribution width
1378	20	362835.0	397559.0	TRIB3	Response to amphetamines
1379	20	362835.0	397559.0	TRIB3	Resting heart rate
1380	20	362835.0	397559.0	TRIB3	Reticulocyte count
1381	20	362835.0	397559.0	TRIB3	Reticulocyte fraction of red cells
1382	20	362835.0	397559.0	TRIB3	Retinopathy in non-diabetics
1383	20	362835.0	397559.0	TRIB3	Schizophrenia
1384	20	362835.0	397559.0	TRIB3	Skin pigmentation
1385	20	362835.0	397559.0	TRIB3	Squamous cell carcinoma
1386	20	362835.0	397559.0	TRIB3	Survival in colon cancer
1387	20	362835.0	397559.0	TRIB3	Telomere length
1388	20	362835.0	397559.0	TRIB3	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes
1389	20	362835.0	397559.0	TRIB3	Visceral adipose tissue adjusted for BMI
1390	20	362835.0	397559.0	TRIB3	circulating leptin levels
1391	20	362835.0	397559.0	TRIB3	circulating leptin levels adjusted for BMI
1392	20	52972407.0	53495330.0	TSHZ2	Bipolar disorder (body mass index interaction)
1393	20	52972407.0	53495330.0	TSHZ2	Coronary artery aneurysm in Kawasaki disease
1394	20	52972407.0	53495330.0	TSHZ2	Urinary tract infection frequency
1395	20	52972407.0	53495330.0	TSHZ2	Warfarin maintenance dose
1396	20	59019254.0	59026654.0	TUBB1	Mean platelet volume
1397	20	59019254.0	59026654.0	TUBB1	Platelet count
1398	20	59019254.0	59026654.0	TUBB1	Platelet distribution width
1399	20	3107573.0	3160196.0	UBOX5	Eosinophil counts
1400	20	3107573.0	3160196.0	UBOX5	Prudent dietary pattern
1401	20	3107573.0	3160196.0	UBOX5	Red blood cell density in sickle cell anemia
1402	20	63939829.0	63956415.0	UCKL1	Metabolite levels  (X-11787)
1403	20	35302566.0	35412141.0	UQCC1	Blood protein levels
1404	20	35302566.0	35412141.0	UQCC1	Developmental dysplasia of the hip
1405	20	35302566.0	35412141.0	UQCC1	Height
1406	20	35302566.0	35412141.0	UQCC1	Lobe attachment (rater-scored or self-reported)
1407	20	35302566.0	35412141.0	UQCC1	QRS interval (sulfonylurea treatment interaction)
1408	20	35302566.0	35412141.0	UQCC1	Spine bone size
1409	20	35302566.0	35412141.0	UQCC1	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)
1410	20	35302566.0	35412141.0	UQCC1	Waist-to-hip ratio adjusted for BMI in active individuals
1411	20	35302566.0	35412141.0	UQCC1	Waist-to-hip ratio adjusted for body mass index
1412	20	45648563.0	45670270.0	WFDC11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers
1413	20	21303304.0	21389827.0	XRN2	Mean corpuscular hemoglobin
1414	20	44885676.0	44908532.0	YWHAB	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)
1415	20	57603846.0	57620576.0	ZBP1	Hippocampal atrophy
1416	20	63743666.0	63831244.0	ZBTB46	Coronary artery disease
1417	20	63743666.0	63831244.0	ZBTB46	Multiple sclerosis
1418	20	63743666.0	63831244.0	ZBTB46	Obesity-related traits
1419	20	52051663.0	52204308.0	ZFP64	Amyotrophic lateral sclerosis
1420	20	52051663.0	52204308.0	ZFP64	Facial morphology (factor 23)
1421	20	52051663.0	52204308.0	ZFP64	Reading disability or specific language impairment (pleiotropy)
1422	20	52051663.0	52204308.0	ZFP64	Testicular germ cell tumor
1423	20	52051663.0	52204308.0	ZFP64	Venous thromboembolism adjusted for sickle cell variant rs77121243-T
1424	20	63707465.0	63736142.0	ZGPAT	Crohn's disease
1425	20	63707465.0	63736142.0	ZGPAT	Inflammatory bowel disease
1426	20	63707465.0	63736142.0	ZGPAT	Lung function (FEV1)
1427	20	63707465.0	63736142.0	ZGPAT	Prostate cancer
1428	20	63707465.0	63736142.0	ZGPAT	Ulcerative colitis
1429	20	41178448.0	41317672.0	ZHX3	Cholesterol, total
1430	20	41178448.0	41317672.0	ZHX3	Coronary artery disease
1431	20	41178448.0	41317672.0	ZHX3	Height
1432	20	41178448.0	41317672.0	ZHX3	Left ventricle wall thickness
1433	20	41178448.0	41317672.0	ZHX3	Non-response to bupropion and depression
1434	20	41178448.0	41317672.0	ZHX3	Resting heart rate
1435	20	41178448.0	41317672.0	ZHX3	Total cholesterol levels
1436	20	47209214.0	47356889.0	ZMYND8	Mean platelet volume
1437	20	47209214.0	47356889.0	ZMYND8	Migraine
1438	20	18288283.0	18316996.0	ZNF133	Body mass index
1439	20	53567065.0	53609907.0	ZNF217	Allergic disease (asthma, hay fever or eczema)
1440	20	53567065.0	53609907.0	ZNF217	Mean corpuscular hemoglobin
1441	20	53567065.0	53609907.0	ZNF217	Mean corpuscular volume
1442	20	53567065.0	53609907.0	ZNF217	Red blood cell count
1443	20	45948653.0	45972172.0	ZNF335	C-reactive protein levels or triglyceride levels (pleiotropy)
1444	20	45948653.0	45972172.0	ZNF335	Coronary artery disease
1445	20	45948653.0	45972172.0	ZNF335	HDL cholesterol
1446	20	45948653.0	45972172.0	ZNF335	HDL cholesterol levels
1447	20	45948653.0	45972172.0	ZNF335	Intelligence (multi-trait analysis)
1448	20	33731657.0	33792269.0	ZNF341	Height
1449	20	2481817.0	2524702.0	ZNF343	Allergic rhinitis
1450	20	2481817.0	2524702.0	ZNF343	Blood protein levels
1451	20	2481817.0	2524702.0	ZNF343	Cognitive performance
1452	20	2481817.0	2524702.0	ZNF343	Conotruncal heart defects (maternal effects)
1453	20	2481817.0	2524702.0	ZNF343	Diisocyanate-induced asthma
1454	20	2481817.0	2524702.0	ZNF343	Glomerular filtration rate in chronic kidney disease
1455	20	59123381.0	59259113.0	ZNF831	Attention function in attention deficit hyperactive disorder
1456	20	59123381.0	59259113.0	ZNF831	Blood pressure
1457	20	59123381.0	59259113.0	ZNF831	Coronary artery disease
1458	20	59123381.0	59259113.0	ZNF831	Crohn's disease
1459	20	59123381.0	59259113.0	ZNF831	Diastolic blood pressure
1460	20	59123381.0	59259113.0	ZNF831	Hypertension
1461	20	59123381.0	59259113.0	ZNF831	Inflammatory bowel disease
1462	20	59123381.0	59259113.0	ZNF831	Lymphocyte counts
1463	20	59123381.0	59259113.0	ZNF831	Lymphocyte percentage of white cells
1464	20	59123381.0	59259113.0	ZNF831	Platelet distribution width
1465	20	59123381.0	59259113.0	ZNF831	Response to antipsychotic therapy (extrapyramidal side effects)
1466	20	59123381.0	59259113.0	ZNF831	Systolic blood pressure
1467	20	59123381.0	59259113.0	ZNF831	Ulcerative colitis
1468	20	49237946.0	49278426.0	ZNFX1	Infant length
1469	20	45857617.0	45879122.0	ZSWIM3	3-hydroxypropylmercapturic acid levels in smokers
1470	20	45857617.0	45879122.0	ZSWIM3	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)
1471	20	45857617.0	45879122.0	ZSWIM3	Waist circumference adjusted for BMI (smoking interaction)
